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ABSTRACT 
 
Hodgkin’s lymphoma (HL) is a lymphoproliferative disorder that was first described by Thomas 
Hodgkin and Samuel Wilks in the first half of the nineteenth century. It is characterised by the 
presence of painless lymphadenopathy, usually in the cervical region. Constitutional symptoms 
are a common presenting feature. Clinical staging is based on the backbone of the Ann Arbor 
staging classification. Patients with advanced disease often have hepatosplenomegaly and bone 
marrow infiltration. True extranodal disease is rare. HL is broadly divided into two distinct 
clinical entities: nodular lymphocyte predominant HL (5%) and classical HL (95%) - which is 
further subdivided into four groups: nodular sclerosis HL, mixed cellularity HL, lymphocyte-rich 
HL and lymphocyte-depleted HL. Most patients are treated with combination chemotherapy 
and involved field radiotherapy. With excellent cure rates of >95% for early stage disease 
nowadays, the challenge is to minimise the adverse long term effects of chemo-radiotherapy, 
while at the same time achieving optimal cure rates.  
There are clear differences in the demographics and clinical presentation of HL between the 
developed world and developing countries. Hence, the main aim of this study was to determine 
the demographics and clinical presentation of HL in a developing, sub-Saharan African 
population, and to compare these findings with findings elsewhere in the world. Secondary 
objectives included assessing the treatment used and response to therapy, prognostic factors 
affecting survival, differences in the presentation between human immunodeficiency virus 
(HIV) positive and negative individuals, the association of HL with tuberculosis, and the 
documentation of the long term effects of therapy.  
Method: This was a retrospective review of all adult patients diagnosed with HL at Chris Hani-
Baragwanath Hospital (CHBH) in Soweto during the period January 1990 – December 2004. 
Results: 163 patients were seen over a fifteen year period. There were 93 males and 70 
females, with a Male(M):Female(F) ratio of 1.3:1. The median age at presentation was 29yrs, 
with an absence of a second peak in older patients. Seventy eight percent of patients had B 
symptoms and 69% had advanced stage disease at presentation. Nodular sclerosis HL was the 
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main histological subtype in the younger, HIV negative population. Mixed cellularity HL was the 
commonest histological subtype seen in older patients and the HIV positive group. Sixty three 
percent of patients had a complete response to first line therapy, 18% a partial response, 2% 
stable disease and 17% progressive disease. Prognostic features of statistical significance that 
negatively affected survival included older patients (>40yrs), patients with advanced stage 
disease and HIV seropositivity. The histological subtype and presence of B symptoms did not 
significantly affect outcome. Twenty three percent of the patients were HIV positive, and 
increasing seropositivity appears to be an emerging trend. Conclusion: HL in patients at CHBH 
displays many clinical characteristics typical of a developing nation, such as the absence of a 
bimodal age distribution, more B symptoms and more advanced stage disease. The 
predominance of the more favourable nodular sclerosis histological subtype in the younger, HIV 
negative population tends to follow the pattern of a developed nation. Older patients, patients 
with advanced stage disease and HIV positive patients have a poorer outcome. The large 
number of patients lost to follow up precludes accurate assessment of long term overall 
survival in the study population, as well as documentation of long term adverse 
effects/complications of therapy.      
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CHAPTER ONE: LITERATURE REVIEW 
 
1.1 INTRODUCTION 
Hodgkin’s Lymphoma (HL) is a lymphoproliferative disorder that was first described by Thomas 
Hodgkin and Samuel Wilks in the first half of the nineteenth century (1). In 1832, Hodgkin 
presented seven autopsy cases with lymphadenopathy, whilst curator of the museum at Guy’s 
Hospital in London. Specimens from three of these cases were preserved in alcohol for many 
years, and in 1998 Poston proved that two of these original cases were indeed that of HL, as 
demonstrated by the presence of the classic Reed-Sternberg (RS) cell and its associated marker, 
CD15 (2,3). Also called lymphogranulomatosis initially, Wilks had named the condition 
Hodgkin’s Disease.  However, as the pathognomonic Reed-Sternberg (RS) cell is now known to 
be of lymphoid origin, the preferred term for the disease is that of Hodgkin’s Lymphoma (1). 
 
1.2 PATHOBIOLOGY OF HODGKIN’S LYMPHOMA 
While Thomas Hodgkin provided the first macroscopic description of HL in 1832, the 
“diagnostic” RS cell was first described by both Carl Sternberg and Dorothy Reed independently  
in  1898 and 1902 respectively (4). The first histologic classification was coined by Jackson and 
Parker in 1944. This was replaced by the Lukes and Butler classification in 1964. In 1965, the 
Lukes-Butler classification was simplified at the Rye conference and was used for over 30 years 
because of its reproducibility and good clinico-pathological correlation. It consisted of four 
histological subtypes: nodular sclerosis, mixed cellularity, lymphocyte predominant and 
lymphocyte depletion (4). 
With advances in histopathology, the Rye classification was addressed in the revised European-
American lymphoma (REAL) classification in 1994. HL was essentially divided into two distinct 
clinical entities: 1) nodular lymphocyte predominant HL (NLPHL), and 2) classical HL (cHL) which 
comprises four subtypes: nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte- 
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depleted. Each subtype differs in their clinical features, amount of fibrosis, number of tumour 
cells, composition of the cellular background and the frequency of Epstein-Barr virus (EBV) 
infection. The REAL classification still stands, and has been adopted by the World Health 
Organisation (WHO) scheme (1) (Table 1.1). Two additional groups have been included in the 
WHO scheme. ‘Unclassifiable HL’ is used in cases where biopsy material is insufficient, or when 
the diagnosis of HL is made at an extranodal site. Then there is a group of ‘Lymphomas with 
Intermediate Features between cHL and Diffuse Large B cell Lymphoma (DLBCL)’ -  previously 
known as grey zone lymphomas. These lymphomas have morphologic and phenotypic features 
of both cHL and DLBCL (4). 
Table 1.1: WHO classification of Hodgkin’s lymphoma 
 Nodular lymphocyte predominant Hodgkin lymphoma 
 Classical Hodgkin lymphoma 
1. Nodular sclerosis classical Hodgkin lymphoma 
2. Lymphocyte-rich classical Hodgkin lymphoma 
3. Mixed cellularity classical Hodgkin lymphoma 
4. Lymphocyte-depleted classical Hodgkin lymphoma 
 
 
1.2.1 Nodular lymphocyte predominant Hodgkin’s lymphoma  
NLPHL comprises about five percent of all HL’s. The tumour usually exhibits a nodular growth 
pattern morphologically. The neoplastic cell is a germinal centre B cell that, unlike Hodgkin and 
RS (HRS) cells, has maintained its B cell program. Called lymphocyte predominant (LP) cells or 
popcorn cells, these cells express CD45 and CD20. CD15 expression is negative and CD30 is 
rarely weakly positive (4). Like germinal centre B cells, LP cells produce immunoglobulin. This is 
via the expression of transcription factor Oct-2 and its co-activator BOB.1, which is consistently 
absent from HRS cells. Unlike with cHL, the EBV genome has never been found in LP cells. Gene 
expression profiling studies have shown that LP cells, like HRS cells, also exhibit constitutive 
nuclear factor kappa B (NFкB) activity (4). 
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The microenvironment in NLPHL consists of a mixture of lymphocytes, plasma cells and 
follicular dendritic cells. The T lymphocytes form characteristic rosettes around the neoplastic 
LP cells, and also exhibit a classic germinal centre phenotype. They produce a chemokine that is 
responsible for B cells homing to the lymphoid follicles. The classic T cell rosetting can be used 
to differentiate cases of NLPHL from T cell/Histiocytic Rich B cell lymphoma (5). 
1.2.2 Classical Hodgkin’s Lymphoma 
1.2.2.1 Pathology of classical HL 
The diagnostic tumour cell of cHL is the characteristic multi-nucleated, giant RS cell. RS cells 
contain at least two nuclei, with their nucleoli occupying more than 50% of the nuclear area. 
Mononuclear variants of the RS cell also make up the neoplastic cell population. These cells, 
known as Hodgkin cells, have the same phenotype as the RS cell.  The HRS cells are usually of 
germinal centre B cell origin, but have lost their B cell programming by multiple mechanisms. 
Hence, their phenotypic expression is not that of a typical B cell. More than 98% of HRS cells 
express CD30, and CD15 expression has been found in approximately 80% of patients with cHL. 
CD20 is less frequently expressed (4). HRS cells do not produce immunoglobulin.   
Although the RS cell is said to be diagnostic of cHL, its presence is not exclusive to HL. Similar 
cells may be seen in reactive lesions like infectious mononucleosis, in some non-Hodgkin’s 
lymphomas (B and T cell), carcinomas, sarcomas and melanomas (4). Hence the diagnosis of 
cHL has to be made on finding the neoplastic cells within an appropriate cellular background. 
The neoplastic infiltrate of HRS cells makes up only 0.1-10% of the tumour bulk (1). The 
inflammatory milieu makes up the rest of the tumour. This consists of lymphocytes, plasma 
cells, eosinophils, histiocytes, neutrophils, fibroblasts and collagen.  Variations in the 
composition of this inflammatory background results in the four histological subtypes of cHL 
mentioned previously. 
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Nodular sclerosis HL  
Nodular Sclerosis (NS)-cHL is the commonest subtype in the developed world (4). It is 
characterised by a thickened lymph node capsule from which emanate broad collagen fibres 
that divide the lymph node into nodules. Also characteristic are lacunar cells - neoplastic cells 
with cytoplasm that is sensitive to formalin fixation, resulting in peri-nuclear condensation of 
the cytoplasm with a clear halo closer to the cell membrane. HRS cells are rare. Mummified 
tumour cells are also seen due to increased apoptosis. Cellular and syncytial variants have been 
described, where the latter is thought to run a more aggressive clinical course. A grading 
system for NS-cHL has been proposed by the British National Lymphoma Investigation (BNLI) 
group. This is based on degree of tumour cellularity, amount of fibrosis and atypia of the 
neoplastic cells. Its real prognostic value is still to be elucidated in larger series (4). 
Mixed cellularity HL 
Mixed Cellularity (MC)-cHL is more common in developing countries and in patients with 
human immunodeficiency virus (HIV) infection. It is characterised by a polymorphous infiltrate 
of background cells which efface the lymph node architecture. Typical HRS cells are seen, as 
well as mummified tumour cells. The interfollicular variant is rare, but needs to be 
differentiated from conditions such as follicular hyperplasia and Castleman’s disease (4). The 
epithelioid cell rich variant has granulomata formation with an epithelioid cell reaction and 
Langhans cells. It needs to be differentiated from a Lennert’s lymphoma (lymphoepithelioid 
lymphoma). HRS cells are always seen after a careful search. 
Lymphocyte-depletion HL 
Lymphocyte Depletion (LD)-cHL is the rarest variant which has the worst prognosis. It is 
identified by a paucity of background lymphocytes with numerous HRS cells. There is a fibrotic 
and a reticular/sarcomatous variant, which must be differentiated from anaplastic large cell 
lymphoma. 
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Lymphocyte-rich HL 
Lymphocyte Rich (LR)-cHL consists of a nodular and much rarer diffuse variant. Under low 
power, the nodular variant may resemble NLPHL. However the immunophenotype of the 
neoplastic cells resembles that of the classic HRS cell. 
1.2.2.2 Biology of classical HL 
The Reed-Sternberg cell 
Despite the fact that HRS cells constitute a small proportion of the tumour bulk, they are 
capable of survival and unrestricted tumour growth. Their neoplastic potential has been 
attributed to two main factors: apoptosis deregulation and constitutive NFкB activity (5). HRS 
cells have been shown to express c-FLIP constitutively, hence down-regulating Fas and evading 
apoptosis. NFкB activity is enhanced by various routes such as CD40 ligand and latent 
membrane protein 1 (LMP-1). Inhibitor of kappa kinase (IкKinase) is activated with liberation of 
NFкB from its inhibitor, inhibitor of kappa B (IкB) (6). There may also be defects in the IкB family 
(4). The end result is activation of nuclear transcription factors that prevent apoptosis. 
The role of Epstein-Barr virus 
Epstein-Barr virus (EBV) integration into the genome of HRS cells has been shown in 20-80% of 
cases of cHL (4). The frequency of EBV-associated HL varies due to a number of factors. EBV-
associated HL is more common in MC versus NS histological subtypes, in developing countries 
versus developed countries, in paediatric and older patients with HL versus young adults and in 
patients with immune deficiency states. Almost all patients with HIV infection and HL are EBV 
positive. HL post transplantation and in patients with congenital immune deficiency syndromes 
is also usually EBV-associated (6). The exact role of EBV in the pathogenesis of HL is yet to be 
determined. However, LMP-1 has oncogenic potential by enhancing bcl 2 expression and by 
acting via the CD40 signalling pathway to evade apoptosis (6).  
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The tumour microenvironment 
Complex interactions between neoplastic cells and the tumour microenvironment aid in tumour 
survival. HRS cells are capable of recruiting cells from the peripheral circulation by the release 
of various cytokines and chemokines. Local expansion of the microenvironment is also 
controlled to a certain extent, and so the inflammatory milieu is manipulated by HRS cells (4).  
Of emerging interest is the influence of the microenvironment cellular component on the 
clinical course of HL. This is of major clinical relevance, since a percentage of patients with HL 
will not respond to first line therapy, despite cure rates of over 85%. Apart from interim PET 
scans, there are no other current modalities to assess, early on, tumour responsiveness to 
therapeutic modalities. Studies by Sanchez-Aguilera et al. and Steidl et al. have identified a 
gene signature for tumour-associated macrophages (with CD68 expression) that is associated 
with primary treatment failure (7, 8). Other gene expression profiling studies have further 
identified signatures associated with good and poor outcome HL. Not only could this be useful 
to assess treatment responsiveness at the outset, but it may also serve as potential molecular 
targets for newer treatment modalities. 
 
1.3 INCIDENCE OF HODGKIN’S LYMPHOMA 
HL is an uncommon malignancy. The worldwide age-standardised incidence rate in 2008 was 
1.0/100,000 (3). The incidence varies geographically, with North America displaying a higher 
incidence than Japan and China, where the condition is relatively rare. Developing countries 
may also show an increased incidence compared to developed countries. There may also be 
regional variations in the incidence of HL within a country. There is a definite increased 
incidence of HL in acquired immune deficient states such as HIV, congenital immune 
deficiencies and post solid organ and bone marrow transplants. These cases are usually EBV 
related. HL is also increased in people with autoimmune disorders or those who have family 
members with an autoimmune condition. Rare, but well documented, is also a tendency for HL 
to exhibit a familial aggregation (9-14).  
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1.4 EPIDEMIOLOGY OF HODGKIN’S LYMPHOMA  
Three main age groups are referred to when looking at the epidemiology of HL: 1) childhood HL 
(CHL);  2) adolescent/young adult HL (AYA HL); and 3) older adult HL (OA HL) (15). These groups 
differ somewhat in biology, clinical presentation, main histological subtype and prognosis. 
CHL represents children ≤14 years of age. This group is characterized by a male predominance, 
an increased prevalence of MCHL and NLPHL, and a higher association with EBV, compared to 
AYA HL. The incidence of HL in this age group is higher in developing countries. This may be 
related to lower socio-economic status and larger family size (15). Overall, the prognosis is very 
good. 
AYA HL, 15-35 years old, usually represents the peak incidence of HL. Adults who are 35-54 
years old have quite a similar clinical presentation. There is no significant gender preference. 
Up to 80% of cases in developed countries are of the nodular sclerosis subtype (16). The 
association with EBV is less than with childhood and older adult HL. The prognosis is good, with 
relative five year survival rates of 90% (15). 
OA HL patients are 55 years and older. This age group presents with more of a mixed cellularity 
subtype, an association with EBV in up to 56% of cases, more B symptoms, more advanced 
stage disease, and overall a poorer prognosis than the other two groups (15). 
In developed countries, there is a tendency for HL to exhibit a bimodal age distribution, with 
peak incidences in the AYA and OA age groups. In developing countries, the second peak in 
older adults is not as obvious. Also, in some areas like the Middle East and parts of Asia, the 
initial peak is noticed more in early childhood (17). 
Other possible risk factors for HL have been highlighted in the paper by Maggioncalda et al (17). 
These include: socioeconomic status (SES), with a higher incidence of HL in people of higher SES 
but a poorer prognosis in patients of lower SES; exposure to pathogens such as measles in 
childhood, that may potentially reduce the risk of HL; strenuous exercise at least twice a week, 
that has been shown to decrease the risk of acquiring HL by 40%; an increased risk of HL in 
 8 
 
active and passive smokers; and regular low dose aspirin exposure that may reduce the risk of 
developing HL. 
1.5 CLINICAL FEATURES OF HODGKIN’S LYMPHOMA 
HL can present in various ways. The presentation may differ slightly depending on the 
histological subtype, geographical area, age group and immune status of the patient. The 
clinical presentation of NLPHL will be addressed separately. 
 The commonest manifestation of HL is that of painless, enlarging lymph node masses, that may 
wax and wane. In 90% of cases the lymphadenopathy (LN) starts in supradiaphragmatic lymph 
nodes, usually in the cervical region (18). Less commonly, lymphadenopathy starts below the 
diaphragm (more common in older patients). The pattern of disease spread is highly 
predictable, with contiguous spread to centriaxial lymph nodes. Mediastinal LN is thus common 
(18). Infiltration of the liver, spleen, bone marrow, bone and lungs may also occur. However, as 
these organs are more deep-seated, the patient may, instead of a mass lesion, present with 
local organ-specific symptoms such as cough and bone pain, deranged laboratory tests or non-
specific constitutional symptoms (18). 
Up to one third of patients with HL experience at least one constitutional symptom or B 
symptom (19). B symptoms are weight loss of >10% body weight in the preceding six months, 
unexplained fever and drenching night sweats. In general, B symptoms correlate with more 
advanced disease, bulk disease and a poorer prognosis. Some patients may present initially 
with B symptoms or fatigue only, thus making the diagnosis of HL more challenging. Other less 
common systemic symptoms include pruritis and alcohol-induced lymph node pain. However, 
in some series pruritis has been described in up to 30% of patients with HL (3).  
Two types of extranodal involvement by HL are described: 1) Direct local extension from 
involved lymph nodes or via adjacent lymphatics is more common. Extranodal sites such as the 
pleura, pericardium, peri-hilar lung, skin, epidural tissue and thyroid are involved in this manner 
(18). This type of contiguous extranodal involvement does not alter the stage of disease 
significantly, and therapy may still be directed as for localized disease. 2) Distant extranodal 
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spread is usually to four main organs: the bone marrow, liver, lung and bone. Distant 
involvement of other extranodal sites such as the brain and gastrointestinal tract is extremely 
unusual, and the diagnosis should be confirmed with tissue biopsy in such cases. Even in HIV 
positive individuals with HL, where true extranodal disease at such unusual sites may be seen 
more frequently than in HIV negative individuals, it is an uncommon finding. 
Autoimmune cytopaenis and other paraneoplastic manifestations are infrequently associated 
with HL (20). Autoimmune haemolytic anaemia and autoimmune thrombocytopenia, if found to 
be associated with HL, usually resolve on treatment of the HL (18). Paraneoplastic neurologic 
manifestations include cerebellar degeneration, subacute myelopathy and motor neuropathies, 
Guillain-Barre syndrome, and limbic encephalitis. Treatment of the HL usually arrests 
progression of, and occasionally improves, the neurology (21). Paraneoplastic renal 
involvement is usually a glomerulonephritis, which can be of many types, such as membranous, 
minimal change or proliferative (22). It may manifest clinically as a nephrotic syndrome, which 
may precede the onset of HL by months to years, and may not resolve on treatment of the HL 
(18). 
Skin manifestations of HL may be seen in 13-50% of patients (23, 24). Most cutaneous eruptions 
are non-specific and can resemble conditions such as dermatomyositis and ichthyosis. Actual 
skin involvement by HL has been reported in 0.5-7.5% of patients (25). Spread is usually 
retrograde from involved lymph nodes, and can be described as papules, infiltrations/plaques, 
nodules/tumours, ulcerative lesions and erythroderma. It may mimic infections like 
scrofuloderma and herpes zoster. Skin involvement by HL is usually a feature of advanced 
disease and may imply a poorer prognosis (25). 
Other abnormalities that have been reported to be associated with HL include: hepatitis, 
cholangitis, vasculitis, hypercalcaemia, hypoglycaemia, coagulopathies and haemophagocytosis 
(26). 
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1.5.1 Nodular lymphocyte predominant Hodgkin’s Lymphoma 
NLPHL requires special mention as the clinical presentation differs somewhat from cHL. It tends 
to involve younger patients, with a male predominance of 2:1. Disease is usually limited, with 
cervical or inguinal LN as the presenting feature (19). B symptoms, bulk disease and extranodal 
involvement are unusual. It is an indolent disease, with lymphadenopathy often persisting for a 
number of years before the diagnosis is made. Cure rates are high with frequent late relapses. 
Unusual presentations and relapse should be confirmed on biopsy, as the condition may co-
exist with a diffuse large B cell Lymphoma or a T cell-rich B cell Lymphoma (18).   
   
1.6 DIAGNOSIS OF HODGKIN’S LYMPHOMA 
As mentioned previously, the definitive diagnosis of HL requires histology to identify the 
characteristic tumour cells (HRS or LP cells) within an appropriate reactive cellular background. 
Thus a complete excision biopsy of an enlarged lymph node is necessary, so that the sparse 
tumour cells are not missed and the lymph node architecture can be appreciated (3). This may 
not always be possible, especially in cases where the biopsy is from an extranodal site, and the 
diagnosis is then more challenging.  
Diagnostic errors in pathological classification have been reported in a number of studies, 
where NHL may be incorrectly diagnosed as HL in about 3-13% of cases. There has also been 
inter-observer variation of up to 8%, in the classification of HL by an expert panel (3). 
The use of cytology and fine needle aspiration (FNA) to diagnose HL has been shown to have a 
high false negative rate of 15-40% (3). Hence, FNA is not reliable for the diagnosis of HL. 
However, occasionally a tissue biopsy sample is not technically possible or may be too invasive, 
and then the clinician may have to rely on an FNA diagnosis in the correct clinical context. The 
role of FNA in the diagnosis of HL may change with improvements in flow cytometry methods 
specific for the detection of HRS cells, such as nine colour assays and gating methods to include 
the HRS cell, as reported by Fromm, et al. (27). NLPHL will still not be able to be detected in this 
manner (27). 
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1.7 STAGING AND INVESTIGATIONS FOR HODGKIN’S LYMPHOMA 
Clinical staging of HL is imperative as it directly affects prognosis and the choice of treatment 
modality. The standard for staging is the Ann Arbor classification and the recent Cotswolds 
Modification (Appendix 1) (28). The Cotswolds modification takes into account modern imaging 
with computerized axial tomography (CT) scanning. It allows for the assessment of bulk disease, 
defined as more than one third of the transthoracic diameter for mediastinal disease, or a 
peripheral mass of ≥10cm in size. It also differentiates extranodal disease that is due to 
contiguous spread, from distant extranodal involvement (28).   
A thorough history is necessary to determine the presence or absence of B symptoms, 
performance status of the patient, pruritis, characteristics unique to HL lymph nodes such as 
change in size, and rarer symptoms like alcohol-induced pain in lymph nodes. 
 Lymphadenopathy needs to be clearly documented as regions involved, above and below the 
diaphragm. A chest X-Ray (CXR) will be useful, but a CT scan of the neck, thorax, abdomen and 
pelvis is mandatory for this. One would also be able to assess on CT scan for the presence of 
bulk disease and extranodal involvement, whether due to direct extension or distant spread.  
A bone marrow (BM) trephine biopsy may indicate bone marrow involvement. Some authors 
are of the opinion that a bone marrow biopsy may not be necessary in stage IA or IIA disease 
with no adverse risk factors, as the probability of a positive BM biopsy in these instances is very 
low (<1%) (28). The pattern of bone marrow involvement in HL is focal, and therefore BM 
biopsy could easily miss involvement at sites other than the iliac crests. With the increasing use 
of positron emission tomography with fluorodeoxyglucose (FDG-PET) with CT as part of initial 
staging to serve as a baseline for comparison to assess treatment response, the question arises 
as to whether PET/CT can replace BM biopsy (29). Studies have shown that the sensitivity for 
bone involvement by HL is better with PET/CT than BM biopsy, conventional CT scanning or 
both (29, 30). A meta-analysis by Pako et al. showed a sensitivity of 76% for FDG-PET, while a 
combination of later studies showed a sensitivity of 85.7%, and indicated that only 1.1% of BM 
involvement would be missed if BM biopsy was omitted (29, 31). The study by Schaefer et al. 
(which included patients with HL and NHL) showed that 42% of patients were upstaged with 
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PET/CT compared to conventional staging when bone involvement was assessed. However, 
only in 14% of these patients (seven patients) did the stage change from limited stage to 
advanced disease, thus potentially warranting a change of therapy (30). 
Other helpful tests would include a full blood count with a differential, blood urea and 
electrolytes, liver function tests, erythrocyte sedimentation rate (ESR), serum calcium, uric acid 
and lactate dehydrogenase (LDH) levels, T cell subsets, immunoglobulin levels and, in the 
appropriate setting, an HIV test. 
The role of PET/CT in the staging of Hodgkin’s Lymphoma 
The use of positron emission tomography with fluorodeoxyglucose (FDG-PET) in the initial 
staging of HL is not part of routine practice. PET/CT is more sensitive than conventional CT 
scanning, picking up 25-30% more disease (32). However, while this may upstage a patient, it 
may also result in overtreatment and additional related toxicity. In favourable, early stage 
disease on conventional CT scan only, cure rates are >95% already. Patients with advanced 
stage disease on conventional CT imaging will get more intensive systemic chemotherapy 
anyway. Thus the role of PET/CT in initial staging is currently limited to clinical trial settings and 
situations where CT scan findings in limited-stage disease are equivocal or radiation field 
planning is difficult (32).  
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1.8 MANAGEMENT OF HODGKIN’S LYMPHOMA 
The modern management of HL has resulted in excellent cure rates, making long term 
complications of chemo-radiotherapy a reality and an important consideration as part of 
disease management. However, despite overall high cure rates of 70-85%, a significant 
proportion of patients will still have primary refractory disease (5-10%), or relapse after a 
complete cure (10-30%) (33). The focus and challenge of HL management these days is on 
efforts to minimize long term toxicities of treatment, while at the same time achieving optimal 
cure rates and survival.  
1.8.1 Risk stratification of patients 
While the search continues for clinically useful biological markers that would determine at the 
outset a patient’s response to conventional therapies (e.g. CD 68 positive macrophages), there 
are a few clinical prognostic markers that are useful in grouping patients according to the 
severity of their disease and their risk of disease recurrence. This is the current basis for risk 
stratification of patients into different treatment groups. Patients with Ann Arbor stages I and II 
fall into limited/early stage HL, while those with stages III and IV have advanced disease. 
The German HL Study Group (GHSG) and the European Organisation for Research and 
Treatment of Cancer (EORTC) have both developed a prognostic scoring system for patients 
with early stage HL that differs only slightly in terms of the criteria used (Appendix 2) (33). 
Patients with Ann Arbor stages I-IIA have early stage favorable HL. Patients with stage IIB HL 
and any one or more of the following risk factors of bulky mediastinal disease, high ESR,  ≥3-4 
lymph node sites involved, extranodal disease and massive splenic disease, will fall into the 
category of early stage unfavourable HL. The GHSG classifies patients with stage IIB disease and 
bulky mediastinal disease or extranodal involvement into the advanced group. 
Patients with advanced disease have been further risk stratified, and an International 
Prognostic Scoring system (IPS)/Hasenclever index, (developed in 1998), is used in this 
subgroup of patients (Appendix 3) (33, 34). The IPS involves seven variables, each of which 
independently affects patient outcome. Patients with no risk factors have a five year freedom 
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from progression (FFP) of 84%, while those with five or more variables have a five year FFP of 
42% (33). 
1.8.2 Risk adapted treatment 
The risk stratification of patients into the above-mentioned subgroups, has allowed for more 
specific tailoring of treatment modalities and intensities, with the aim of avoiding the 
overtreatment of low risk patients and the under-treatment of high risk patients, while at the 
same time attempting to minimize the long term toxicities of chemo-radiotherapy. 
Early stage Hodgkin’s Lymphoma 
For early stage favourable HL, combined modality therapy (CMT) has been shown to be 
superior to chemotherapy alone (35). Extended field radiotherapy only for early stage disease is 
no longer used, due to high treatment-related toxicity and high relapse rates. The current 
standard of care is to administer two cycles of ABVD (doxorubicin, bleomycin, vinblastine and 
dacarbazine) followed by 20Gy of involved field radiotherapy (IFRT). More than 95% of patients 
can be cured with this approach. A large study by the GHSG involving 1,370 patients showed no 
difference in response to treatment, progression free survival (PFS) and overall survival (OS) 
with two cycles versus four cycles of ABVD and 20Gy versus 30Gy of IFRT (33).  
For early stage unfavourable HL, CMT is also the standard of care, with four cycles of ABVD 
followed by 30Gy IFRT. The five year progression-free survival (PFS) is about 85-90% (35). 
Intensification of chemotherapy using two cycles of escalated BEACOPP (bleomycin, etopiside, 
adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone) with two cycles of 
ABVD versus four cycles of ABVD in 1,655 patients showed an improved freedom from 
treatment failure (FFTF) at the expense of increased treatment toxicity with escBEACOPP, with 
no improvement in OS (33). 
Advanced stage Hodgkin’s Lymphoma 
Numerous chemotherapy regimens have been compared for the treatment of advanced HL 
over the past few years. The results of many randomized trials have shown the best results with 
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ABVD (33). The five year PFS rates are around 70% (35). In addition to the efficacy of ABVD, it is 
also easy to administer and is well tolerated by patients. The use of escBEACOPP compared to 
ABVD, may result in improved PFS, but it is still unclear whether overall survival is improved 
(35). The problem with escBEACOPP is increased myelosuppression in the short term and 
infertility in the long term, making it a less feasible option in younger patients. It has also been 
associated with an increased incidence of myelodysplasia and acute leukaemia, though the 
numbers to date are small.  
The role of radiotherapy in advanced disease is not as clear as in early stage disease. A 
randomized EORTC trial showed no benefit from radiotherapy in terms of disease recurrence 
for patients in complete remission (CR), but patients in partial remission (PR) had a clear 
benefit. The GELA group confirmed this finding for patients in CR. Initial results from the GHSG 
HD15 trial, using FDG-PET to guide consolidation radiotherapy, has shown a possible role for 
radiotherapy in PET positive patients with residual active disease (35). 
1.8.3 Response adapted treatment and the use of interim PET/CT scans 
While the use of clinical prognostic indices is helpful in grouping patients for risk stratified 
therapy, it does not take into account individual variations in response to treatment. Interim 
PET scans may complement and possibly supercede the value of prognostic scoring systems. 
FDG-PET performed early on in treatment may provide some guidance as to the chemo-
sensitivity of a tumour and to the risk of relapse. 
PET/CT scanning in patients with HL is of particular use for a couple of reasons. FDG-PET scans 
are able to distinguish metabolically active lymph nodes that are due to disease, from normal 
lymph nodes. FDG-PET can also reliably determine whether a residual mass (quite common in 
HL) consists of fibro-necrotic scar tissue or viable tumour cells. Accurate localization of disease 
is possible with the use of integrated PET/CT scanners. 
As with any new modality, it is important to understand the limitations of FDG-PET and to await 
the results of ongoing randomized trials to assess its appropriate use in clinical practice.        
FDG-PET has a high negative predictive value (NPV) and a weaker, more variable positive 
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predictive value (PPV). Hence, while a negative PET scan may be more reliable and clinically 
useful, a positive scan needs to be interpreted with caution. False positive PET scans may be 
due to infection, inflammation and supraclavicular brown fat. A negative PET scan also does not 
totally exclude active tumour due to the limit of resolution of current scanners (36).  
Early stage Hodgkin’s Lymphoma 
Since cure rates are high with current recommendations for treatment of this sub-group of 
patients, the question arises as to whether IFRT can be totally omitted to further minimize the 
adverse long term effects of treatment. Eighty percent of patients with early stage disease have 
a PET negative response after two to three cycles of ABVD, and their PFS will be 95% whether 
treated with further chemotherapy or radiotherapy (32).The HD6 trial showed a small reduction 
in five year FFP in patients with limited, non-bulky disease treated with six cycles of ABVD alone 
(87%), compared to those in whom radiotherapy was added (93%), but better overall survival in 
the ABVD group (37). The feeling is that a modestly inferior PFS may be acceptable with the 
omission of radiotherapy, as toxicity will be reduced and effective second line treatment is 
available for the small number of patients who will relapse. Currently, three large randomized 
trials are assessing the need for radiation or further chemotherapy or just observation, based 
on PET findings after two to three cycles of ABVD.  The final results of these trials are eagerly 
awaited.   
 Advanced disease 
Gallamini et al. showed initially that the use of PET post cycle two chemotherapy could predict 
the outcome for patients with advanced HL. In 260 poor risk patients they found that those 
who were PET negative had a two year PFS of 95%, as opposed to PET positive patients whose 
two year PFS was 13% (38). Interim PET positive patients are therefore at higher risk of relapse 
than interim PET negative patients. This observation could potentially serve as a guide for 
escalation or de-escalation of chemotherapy in individual patients. However, imaging has been 
difficult to interpret consistently, and a significant proportion of PET positive patients will still 
be cured by continuing their original treatment regimen, rather than escalating treatment 
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intensity with added toxicity. Thus, interim PET scanning is not recommended for advanced 
stage HL, except in the context of a clinical trial (32). 
1.8.4 End of treatment PET/CT 
In patients with advanced disease, PET/CT is useful in assessing residual masses at the end of 
chemotherapy. Due to the high NPV of PET, patients with a negative scan at the end of 
chemotherapy can be assumed to be in complete remission (CR). Treatment can be stopped in 
these patients, as further chemotherapy or radiotherapy has been shown to be of no benefit. 
About 25% of patients with a residual mass at the end of chemotherapy will be PET positive. 
These patients are currently treated with radiotherapy, despite the knowledge that a certain 
percentage of scans will be false positive, and some of these masses may be radio-resistant (as 
chemo-resistance and radio-resistance often co-exist). Results of current trials addressing this 
issue will hopefully clarify further management (32). 
1.8.5 Management of refractory/relapsed disease 
Five to ten percent of patients will have primary refractory disease. The prognosis for these 
patients is poor, as second line chemotherapy has not been able to achieve good cure rates, 
with long term disease free survival (DFS) in only five to ten percent of patients (39). High dose 
chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is the treatment of 
choice in these patients. 
About 10-30% of patients who have achieved a complete remission (CR) will relapse. The risk of 
relapse is highest in the first one to two years, and is very low at 10 years post CR. At 10-15 
years post treatment for HL, the concern about the adverse long term effects of therapy 
administered supercedes that of relapse. More than 80% of patients in first relapse will respond 
to salvage chemotherapy, with a median survival of four years. There has been no direct 
comparison between the various salvage regimens, so no regimen is preferred. Despite good 
responses to salvage chemotherapy, patients still relapse and succumb to disease progression 
and treatment complications. Hence, most patients with relapsed disease are now managed 
with HDCT and ASCT if eligible. Phase II studies and two randomized trials have confirmed an 
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improved outcome with ASCT compared to conventional chemotherapy, with both trials 
showing a three year event free survival of more than 50% in the transplant arms (40, 41). 
1.8.6 The role of stem cell transplantation in the management of HL 
As mentioned above, HDCT and ASCT is now the standard of care for patients in first relapse. A 
subset of patients (usually those with localized disease at relapse), may however still benefit 
from radiotherapy. For patients with primary refractory disease, the outcome after HDCT and 
ASCT is not as promising as in patients who relapse. However, this sub-group of patients may 
still have a 20-30% chance of cure with ASCT after failing first and second line chemotherapy 
(42). 
PET/CT scanning may have a role to play prior to using highly toxic therapy in patients 
considered for transplant. PET can be used to assess response to second line chemotherapy 
prior to HDCT and ASCT. A positive PET scan prior to transplant is associated with a higher 
relapse rate and a poorer outcome post ASCT. However, not all patients with a positive PET 
scan will relapse post transplant (7-56% in studies do not relapse), and thus a positive scan 
should not be the reason for denying a patient HDCT and ASCT, which may be their best 
currently available chance of cure (32). 
For patients who relapse after ASCT, the possibility of an allogeneic stem cell transplant (allo-
SCT) exists. Myeloablative regimens are highly toxic and result in increased morbidity and high 
transplant-related mortality of 20%. According to transplant registry data, allo-SCT has not been 
superior to ASCT in terms of PFS and DFS, despite lower relapse rates (42). The increasing 
practise of reduced intensity conditioning (RIC) allo-SCT in the United Kingdom has been 
promising. When RIC allo-SCT was compared to myeloablative allo-SCT, RIC regimens were 
associated with a lower transplant-related mortality. The increased incidence of chronic graft 
versus host disease (GVHD) in RIC allo-SCT resulted in lower relapse rates, and this was 
associated with an improved PFS and OS (42). The possibility of a graft-versus-Hodgkin effect in 
patients treated with RIC regimens also provides potential for donor lymphocyte infusions as a 
therapeutic option. 
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The use of monoclonal antibodies and histone deacetylase inhibitors is being tested in clinical 
trials to assess their utility as maintenance therapy post ASCT to decrease relapse rates. If 
successful, these agents could potentially be used in the allo-SCT setting as well. 
1.8.7 Novel therapies in the management of Hodgkin’s lymphoma 
The development of novel, targeted therapies offers some hope for patients who are chemo-
resistant or cannot tolerate the toxicity of conventional regimens. 
Monoclonal antibodies  
Preparations of monoclonal antibodies to CD30 were previously disappointing due to low 
responses and high toxicity. Current preparations are much more promising and better 
tolerated. Brentuximab vedotin is an antibody-drug conjugate comprising an anti-CD 30 
chimeric monoclonal antibody, conjugated to an anti-tubulin, auristatin. In a phase II trial of 102 
patients who failed ASCT, the overall response rate was 75%, with 34% of patients achieving a 
CR. The response was durable, with a median duration of 47 weeks (43). 
Histone deacetylase (HDAC) inhibitors  
Panobinostat showed an overall response rate of 27% in 129 patients who failed ASCT. The 
median PFS was 5.7 months (44). 
Mammalian target of rapamycin (mTOR) inhibitors 
Everolimus is an mTOR inhibitor that showed an overall response rate of 47% in patients who 
had relapsed disease. Eight patients had a PR and one patient a CR, with four of these patients 
being free from progression at 12 months (45). 
Rituximab 
Rituximab, a chimeric monoclonal antibody to CD 20, has shown good responses in patients 
with relapsed and refractory NLPHL. Similar good results were seen in patients with cHL who 
had multiple relapses. However, these responses have been short-lived. Furthermore, patients 
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with NLPHL who are treated with Rituximab may relapse with a CD 20 negative T cell-rich B cell 
NHL (46). 
Other agents 
Cytotoxic agents such as bendamustine, vinorelbine and gemcitabine have produced responses 
in patients with HL who have been heavily pretreated. The immunomodulatory agent 
lenalidomide has also shown promising results when used as a single agent, and trials are 
ongoing in relapsed HL patients and as part of combination chemotherapy in elderly patients 
with HL (3). 
1.8.8 Management of nodular lymphocyte predominant HL 
NLPHL is of an indolent nature, with a 10 year OS of about 90%. For patients who have localized 
disease that has been fully excised, a ‘watch and wait’ approach is thus reasonable. Patients 
with localized disease may also benefit from 20-30Gy of IFRT, with the 10 year PFS for stage I 
being 85% and 65% for stage II disease (35). Patients with more advanced disease are usually 
treated with combination chemotherapy as in cHL. Rituximab is often added to ABVD. A study 
of single agent Rituximab in patients with relapsed disease has shown an overall response rate 
of 94%, but early recurrence. Trials to optimize chemotherapy (with Rituximab) are in progress 
(33). 
1.8.9 Management of the elderly patient with HL 
With the second peak in incidence of HL in developed countries in patients over 60 years of age, 
special consideration needs to be given to the management of HL in this sub-group. Elderly 
patients with HL tend to do worse than their younger counterparts. DFS and OS rates are about 
20% lower than for younger patients with HL. There are a few reasons for this. Older people 
have more co-morbid disease, e.g. cardiovascular and respiratory. The elderly patient with HL 
presents with more adverse risk factors. Older patients also generally tolerate cytotoxic 
chemotherapy poorly, posing a challenge to administer chemotherapy with an intention to 
cure. Similarly, salvage regimens may be intolerable to the elderly patient. A small study of 
CHOP-21 (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy in elderly 
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patients has shown a three year PFS of 82% and OS of 91% (47). It is hoped that newer agents 
such as monoclonal antibodies, which are better tolerated, provide a new avenue for the 
optimal management of the elderly patient with HL. 
   
1.9 LATE EFFECTS OF TREATMENT FOR HODGKIN’S LYMPHOMA 
Acute toxicity from HL therapy is not very different from the treatment of other cancers. Side 
effects that are dose-limiting include myelosuppression, specific side effects of chemotherapy 
such as neurotoxicity of vinca alkaloids, and direct organ toxicities from radiation therapy. 
More unique to the management of HL is the long term sequelae of chemotherapy, radiation 
therapy and stem cell transplantation. The reason for this is that most patients with HL are 
young, and with the excellent cure rates of 70-85% (and more with early stage favourable 
disease) nowadays, patients are living much longer and hence the late effects of treatment are 
more apparent. 
In 1962, Kaplan developed the concept of extended field radiotherapy (EFRT) for the treatment 
of HL. The five year survival for this previously lethal disease increased to 70% for patients with 
localized disease (48). In the 1970’s, MOPP (mechlorethamine, oncovin, procarbazine, 
prednisone) chemotherapy was used and in the 1980’s, ABVD was introduced for patients who 
were resistant or refractory to MOPP. Stem cell transplantation also became available as a 
treatment option. By the 1990’s, the late effects of chemo-radiotherapy became more 
apparent (49). 
A number of late effects of therapy for HL are noted. These complications vary between 
individuals, based on the period in which the patient was treated and on the modality of 
treatment that the patient received. All patients should be made aware of these possible late 
complications, preferably prior to commencing treatment, but definitely at the end of 
treatment so that adequate follow-up and screening is facilitated. A brief overview of specific 
complications is given below and some guidelines for screening, so that complications may be 
detected early. 
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1.9.1 Secondary malignancies 
Secondary cancers are usually due to radiotherapy (RT). They are responsible for most of the 
morbidity and mortality experienced by HL survivors. The cumulative incidence of developing a 
second malignancy is 11% at 20 years and 26% at 30 years post treatment. The commonest 
malignancies are solid organ tumours such as non-melanoma skin cancer, lung cancer, breast 
cancer and colo-rectal cancer. Sarcomas and non-HL may also occur. These cancers manifest at 
a median of 14.3 years after treatment, and the risk continues to rise with time (50). Adolescent 
females are at greatest risk for breast cancer, especially those who have received mantle 
radiotherapy at doses of >30Gy (15).  
Myelodysplasia and acute leukaemia are usually due to the use of alkylating agents in 
combination chemotherapy such as MOPP and BEACOPP. The median latency is three years, 
with a usual initial presentation within 10 years (49). 
The introduction of involved field radiotherapy (IFRT) and the recent concept of involved node 
radiotherapy (INRT) has resulted in substantially reduced volumes of radiation to the lungs, 
heart and breast tissue, for patients previously receiving mantle RT. The standard of care for 
early stage disease is 20Gy of IFRT, so radiation doses are even reduced. This results in breast 
tissue receiving 80% less of the radiation exposure than with previous mantle RT. These 
measures have shown to reduce the risk of a second malignancy (48). 
For patients at increased risk of breast cancer, monthly breast self examination and annual 
clinical examination is recommended. Annual mammography should be performed eight years 
post treatment or from the age of 25, whichever is later (51).   
Patients must be advised to use sun-protective measures and monthly skin self-examination, 
with recommended annual dermatologic assessment of skin lesions.  
For patients who received pelvic, abdominal or spinal RT >30Gy, colo-rectal screening should 
commence at the age of 35 or 15 years post treatment and repeated with a frequency 
depending on initial findings (52).                                                                                                                              
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Patients must stop tobacco use, as this further increases the risk of lung cancer. 
 
1.9.2 Cardiovascular disease 
 
Long term cardiac effects may be due to mainly mediastinal RT or anthracycline use, and have a 
latency of 10 years. The cumulative risk of cardiac disease is 5-10% at 15 years, 16% at 20 years 
and 34% at 30 years (53-55).  
 
Almost half of cardiac complications are due to accelerated coronary artery disease caused by 
mediastinal RT at doses of >35Gy. The use of IFRT often involves the superior one third of the                                                                                                                                                                                                                                
heart, and hence the coronary arteries are still within the radiation field. However, IFRT and 
current recommended treatment doses have reduced cardiac exposure by 60% (48). The use of 
involved node RT may have a role to play in limiting coronary artery radiation exposure, but it is 
unclear whether this should be the standard of care currently. Established risk factors for 
coronary artery disease further accelerate the atherosclerotic process.    
                                                                                                                                       
Myocardial perfusion may also be affected by mantle RT, causing left ventricular (LV) 
dysfunction. Anthracycline therapy may cause LV dysfunction and congestive cardiac failure 
more than one year after treatment if doses above the limit for toxicity (e.g. >550mg/m² for a 
drug such as adriamycin) are administered. However, a significant proportion of patients 
receiving less than the toxic dose will develop subclinical cardiomyopathy at a median follow up 
of eight years after treatment (49).                                                                                                                                  
 
Mediastinal RT may cause cardiac valve dysfunction, with a risk of five percent in 20 years.           
Accelerated atherosclerosis may occur in the carotid and subclavian arteries post RT, leading to 
increased risk of stroke and transient ischaemic attacks. 
 
Patients at risk for cardiovascular disease need to be advised not to smoke, and existing risk 
factors need to be aggressively managed. Screening may commence 10 years post treatment 
with a baseline stress test and echocardiogram. Echocardiogram will not only detect valvular 
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lesions, but may also provide insight as to LV function. There is evidence that early anti-failure 
therapy, such as the use of angiotensin coverting enzyme (ACE) inhibitors and carvedilol, for 
asymptomatic LV dysfunction may prevent progression of cardiomyopathy (56). 
Careful clinical examination is mandatory to assess for non-coronary vascular disease, where 
bruits or absence of pulses will warrant doppler imaging.                                                                                             
1.9.3 Thyroid disease 
Up to one third of patients may develop thyroid abnormalities. The commonest manifestation 
is hypothyroidism, which may be subclinical. RT damages the thyroid vasculature. Paediatric 
patients are much more sensitive to these effects. Other manifestations may be Grave’s 
disease, thyroiditis, multinodular goiter, adenoma, malignancy and rarely secondary 
hypothyroidism. 
Patients should have annual thyroid examination and thyroid function tests (49). Subclinical 
hypothyroidism must also be treated with eltroxin, to avoid over-stimulation of a gland that is 
already prone to malignancy. A palpable nodule needs to be investigated in its own right. 
1.9.4 Infertility 
With a peak incidence of HL in patients in their reproductive years, infertility is an issue that 
cannot be ignored. The culprits are usually alkylating agents, and hence ABVD is a more 
appropriate choice of chemotherapy in younger patients, rather than BEACOPP and the 
previously used MOPP regimen. Pelvic RT and total body irradiation also cause damage to the 
gonads. Premature menopause may occur as a result of ovarian failure. 
Patients need to be informed as to the risk of infertility prior to therapy, and treatment needs 
to be tailored to preserve fertility or avoid permanent effects if possible. Males should be 
informed of the option of sperm banking. Premature menopause needs to be managed in its 
own right, especially with measures to protect against osteoporosis. 
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1.9.5 Other late effects 
Pulmonary disease may be due to mediastinal RT or the use of bleomycin, usually at a dose of 
>400mg. Elderly patients may have an idiosyncratic reaction to bleomycin at lower doses (57). 
Pulmonary manifestations include interstitial pneumonitis, pulmonary fibrosis and acute 
respiratory distress syndrome.  
Chronic fatigue is a common manifestation in over one third of patients. It may persist for long 
after treatment is completed. The cause is unclear, but may be cytokine related. Reversible 
causes need to be investigated and treated. 
Psychosocial issues have a direct impact on health-related quality of life. HL survivors may 
experience anxiety, depression and post traumatic stress disorder symptoms long after 
treatment has been completed. It is important to enquire about social support, financial 
worries and return to work and school/studies at follow up visits.  
 Impaired immunity may persist despite treatment discontinuation and cure of HL. Patients 
should receive the influenza vaccine annually, and those who have received splenic irradiation 
or had a splenectomy must receive pneumococcal, meningococcal and haemophilus 
vaccinations. 
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1.10 HIV AND HODGKIN’S LYMPHOMA 
HL and HIV both present with a peak incidence in young adults, and so it was initially thought 
that the co-existence of these two conditions was purely co-incidental. However, with the 
advent of anti-retroviral (ARV) therapy, patients with HIV began to live longer, and HL was seen 
with an increased incidence even in these older patients. HIV-associated HL (HIV-HL) differs 
somewhat from HL in HIV negative patients in terms of incidence, pathology, clinical features, 
response to treatment and prognosis. Some of these differences are highlighted below. 
1.10.1 Incidence and epidemiology 
HL is a non-AIDS-defining cancer, with a ten-fold increased incidence in HIV positive patients 
compared to the general population (9, 58). While AIDS-defining cancers like NHL and Kaposi’s 
sarcoma are decreasing in incidence with the advent of highly active anti-retroviral therapy 
(HAART), the incidence of non-AIDS-defining cancers like HL, anal carcinoma, lung cancer and 
hepatocellular carcinoma is on the rise (59).  
Powles et al confirmed in their prospective cohort of 11,112 HIV positive patients with cancer, 
that HAART was associated with an increased risk of HL (60). A possible explanation is that 
immune reconstitution facilitated by HAART results in an influx of CD4 cells and other 
inflammatory cells into the tumour microenvironment, and that these provide proliferation 
signals for the HRS cell. 
Almost all cases of HIV-HL are EBV associated. The impaired immunity in HIV allows for 
uncontrolled proliferation of EBV. The EBV latent membrane protein 1 (LMP-1) is found in 
practically all tissue samples of HIV-HL. LMP-1 is responsible for constitutive NFƙB expression 
that results in activation of signalling pathways responsible for cell growth and decreased 
apoptosis. 
1.10.2 Pathology 
Most cases of HIV-HL in the pre-HAART era were of the mixed cellularity and lymphocyte 
depleted subtypes of classical HL. These were cases that were associated with marked immune 
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suppression. With the advent of HAART, mixed cellularity HL still remains the commonest 
histological subtype in HIV-HL, but nodular sclerosis HL is increasing in incidence again (59). 
1.10.3 Clinical Features 
HIV-HL displays an aggressive clinical course. Most patients present with B symptoms and 
advanced stage disease. Extranodal involvement is common, present in 17-62% of patients in a 
number of studies, with the commonest extranodal site being the bone marrow (40-59%), 
followed by the liver (17-40%) and then the spleen in 20-30% of cases (9). HAART exposure 
prior to the diagnosis of HL may modify the clinical picture somewhat. Data from the Italian 
Cooperative Group on AIDS and Tumours (GICAT) showed that patients who were on HAART 
already at the time of HL diagnosis were older, had less B symptoms, had higher leucocyte and 
neutrophil counts, and higher haemoglobin levels (58). 
1.10.4 Management 
Supportive measures 
The optimal management of the HIV-HL patient requires supportive measures, in addition to 
chemotherapy. Patients should ideally be on HAART and, depending on the CD4 count, 
chemoprophylaxis for opportunistic infections such as pneumocystis jerovecii pneumonia may 
need to be instituted. Growth factor support is often required, as these patients tend to 
tolerate chemotherapy less well and often have bone marrow involvement by HL with impaired 
reserve. 
Specific treatment 
As most patients have advanced disease, treatment usually involves combination 
chemotherapy. Regimens such as ABVD, EBVP, MOPP/ABV hybrid and Stanford V have all been 
used. Remission rates and overall survival are generally lower than for the general population 
(9). Special considerations in this group include potential interactions between anti-retrovirals 
and anti-infectives with chemotherapy. 
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The benefits of HAART 
Patients on HAART do better than HAART-naïve patients. HAART allows for the delivery of 
standard doses of chemotherapy on time, and there is less morbidity from opportunistic 
infections. In a study by the Spanish group GESIDA, patients on HAART had higher complete 
remission rates, and this translated into better overall survival rates (61). HAART has also 
allowed for the option of salvage therapy by autologous stem cell transplantation in relapsed 
patients with HIV-HL. However, patients on HAART still do worse than their HIV negative 
counterparts (9). 
The role of PET scans 
The role of PET scanning in HIV-HL has yet to be clearly defined. PET scans have to be 
interpreted with great care. HIV positive patients may have positive PET scans for reasons other 
than malignancy. Areas of increased uptake in the lung and oesophagus may be due to HIV-
related infections. Nodal uptake may also be due to opportunistic infections such as 
tuberculosis and other malignancies like Kaposi’s sarcoma (58). Baseline PET scans prior to 
treatment may be useful in this setting.         
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1.11 TUBERCULOSIS AND HODGKIN’S LYMPHOMA  
The association between tuberculosis (TB) and malignancy is well documented. This association 
is even more significant with HL, as demonstrated by Kaplan et al in a large series of 201 
patients with malignancy (62). The increased incidence of TB in HL is for a number of reasons. 
Patients with HL have impaired cellular immunity, which predisposes them to infection with 
intracellular organisms such as mycobacterium species (63). Furthermore, the chemotherapy 
used to treat the HL contributes to the immune suppression, facilitating reactivation of 
dormant TB bacilli and dissemination of infection. This association between TB and HL may be 
further enhanced by the co-existence of HIV infection in areas where the condition is epidemic.  
TB and HL have a similar clinical presentation with regards to constitutional symptoms, the 
presence of lymphadenopathy and possibly hepatosplenomegaly, bone marrow involvement 
and overlapping CXR and CT scan features. Some of the skin manifestations of HL may also 
mimic scrofuloderma that is seen in TB (25). Both conditions may also present with 
granulomatous reactions histologically in LN and the bone marrow, which may be necrotising in 
HL as well as in TB. This clinical overlap often leads to a delay in the diagnosis of either 
condition if they co-exist. Furthermore, TB presenting during or after the treatment of HL may 
be confused with refractory or relapse of HL respectively (64).  
While three-dimensional single-proton emission computed tomography (3D-SPECT) and FDG-
PET scans may be useful, they cannot fully differentiate metabolically active tissue due to 
infection, from malignancy. A case report by Bakheet et al, demonstrated generalized intense 
FDG-PET uptake by lymph nodes due to TB in a patient with breast malignancy, which was 
initially confused for metastatic disease or lymphoma (65). Visual interpretation with 
quantitative analysis and specific cut-off values may help with the specificity of PET scans. 
However, the most sensitive and specific means of differentiating TB from HL is by tissue biopsy 
(64, 25). Both conditions can co-exist in the same LN or bone marrow sample. The pathologist 
needs to look carefully for HRS cells with characteristic staining properties, and perform stains 
for acid-fast bacilli, cultures for mycobacterium TB and in difficult cases, polymerase chain 
reaction (PCR) to identify TB organisms.  
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It is imperative that clinicians and pathologists be aware of the close association between TB 
and HL, especially in areas where TB is endemic, thus ensuring prompt diagnosis of both 
conditions and timeous institution of appropriate therapy. More work needs to be done 
regarding the interpretation of PET scans in the patient with TB and malignancy, thus hopefully 
providing the clinician faced with diagnostic and management dilemmas with more specific and 
less invasive solutions. 
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CHAPTER TWO: PATIENTS AND METHODS 
 
2.1. Study design and population 
This is a retrospective study of all adult patients (according to hospital admission criteria - males 
over the age of 12 and females over the age of 14) presenting at Chris Hani-Baragwanath 
Hospital, Clinical Haematology Unit, with a confirmed histological diagnosis of Hodgkin’s 
lymphoma, during the period January 1990 to December 2004.  
2.2. Methods 
Each patient’s haematology file was reviewed in great detail. Demographic, clinical, laboratory 
(including histology), radiographic and management parameters for each patient were 
documented on a standardised data collection sheet. Response to treatment, complications, 
relapse (where applicable), date last seen, date of death (where applicable) and overall survival 
were also documented.  
2.3. Data analysis 
Data was recorded in an EXCEL spreadsheet and analysed in Stata by a statistician. Missing data 
was excluded from the analysis. Continuous variables such as age, duration of 
lymphadenopathy, blood parameters and number of chemotherapy cycles, were reported as a 
median with the range and/or interquartile range. Age distribution between HIV positive and 
negative patients was compared using the non-parametric Wilcoxin rank-sum test. Frequencies 
of categorical variables such as gender, B symptoms, performance status, site of 
lymphadenopathy, etc. were compared using the Pearson Chi-Squared test. When sub-groups 
of patients were compared for categorical variables, the Fisher’s exact test was used. A life 
table analysis and Kaplan-Meier survival curves were used to assess overall survival, and to 
determine prognostic variables affecting survival. Where survival between groups of patients 
was compared, the stratified log-rank test (stratified for age) was used. A p-value of <0.05 was 
considered to be significant for all tests used.      
 32 
 
CHAPTER THREE: RESULTS 
 
3.1. Patient characteristics 
A total of 163 patients with HL were seen between January 1990 and December 2004. The 
median age was 29 years (range 13-87yrs). The inter-quartile range (IQR) was 23-39 years. 
There was no clear evidence of a second peak in incidence in older patients, as demonstrated 
by the histogram below (Figure 3.1). Thirty seven patients (23%) were over the age of 40 years. 
 
                               
        Figure 3.1: Histogram for age 
There were 93 males (M) and 70 females (F), with a M:F ratio of 1.3:1. One hundred and 
fifty patients were Black (145 were South African; two were from Mozambique, two 
from Swaziland and one from Lesotho; all employed in South Africa), six patients were 
Indian (South African born), four patients were Coloured, one patient was Caucasian and 
two patients were classified as ‘other’ – one of whom was Moroccan and the other from 
the Comores; both residing in South Africa. 
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3.2. Clinical features 
Performance status (PS) was assessed using the Eastern Cooperative Oncology Group (ECOG) 
grading system (Appendix 4). The PS was known in 132 patients. Most patients had a PS of 0 
and 1 (see Figure 3.2 below). 
                       
                                     Figure 3.2: Distribution of performance status 
B symptoms were defined as unexplained weight loss of more than 10% body weight in the 
preceding six months, drenching night sweats, and unexplained fever of >38:C in the previous 
two to four weeks for which there was no other cause. The presence or absence of B symptoms 
was known in 156 patients. Thirty four patients (22%) had no B symptoms, while 122 patients 
(78%) had at least one or more of the above-mentioned B symptoms. Twenty one of 154 
patients (14%) complained of severe pruritis.    
Forty one of 161 patients (26%) had a history of tuberculosis (TB). Nine patients (6%) had TB 
prior to the diagnosis of HL (five were much earlier in childhood). Of the remaining 32 patients 
(20%), the diagnosis of TB and HL was simultaneous in eight patients, TB was diagnosed whilst 
on treatment for HL in 19 patients, TB was diagnosed on relapse of HL in one patient and four 
patients had TB whilst in remission from HL. Six of the 32 patients also had a history of TB prior 
to the diagnosis of HL, and thus had recurrent TB. Eleven of 41 patients (27%) with TB were also 
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HIV positive (forty six patients (28%) in the study were HIV positive; see page 51). Seventeen of 
32 patients had pulmonary TB only, three patients had TB meningitis, three patients had TB 
lymphadenitis, three patients had TB of the bone marrow only, and six patients had 
disseminated TB (four were HIV positive).   
The median duration of lymphadenopathy (LN) or symptoms relating to HL prior to 
presentation to hospital was five months (range 0.3-132mnths; IQR of 3-11mnths). The 
characteristics of LN at presentation are highlighted in Table 3.1 below. Most patients 
presented with involvement of supra-diaphragmatic LN, including the cervical region. 
Generalised lymphadenopathy was defined as involvement of three or more lymph node 
regions. Bulk disease was defined as involvement of more than one third of the transthoracic 
diameter for mediastinal LN, or a peripheral lymph node mass of ≥10cm, and could be 
evaluated in 151 patients.  In the 10 patients who had no LN, the diagnosis of HL was made at 
an extranodal site. Distribution of LN could not be accurately evaluated in 16 patients (10%) 
because imaging results were not available for these patients.   
Table 3.1: Characteristics of lymphadenopathy at presentation 
                                                                         
 
 
 
 
 
 
Hepatomegaly was present in 61 of 149 patients (41%) at presentation. The hepatomegaly was 
clinically present in 54 of these patients (36%), and radiological findings (ultrasound or CT scan 
imaging) concurred in 20 of these patients (13%). The remaining seven patients had 
Characteristic Number of patients Percentage 
Supra-diaphragmatic LN 129 79% 
Cervical LN 125 78% 
Sub-diaphragmatic LN only 8 5% 
Generalised LN 86 53% 
No LN 10 6% 
Non-evaluable 16 10% 
Bulk disease 26 17% 
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hepatomegaly on imaging only. Six of 143 patients (4%) had liver lesions, described as hypo-
echoic lesions on sonar or hypodensities in the liver on CT scan. Three patients had large liver 
masses on imaging. The liver and spleen characteristics of the nine patients with liver 
lesions/masses are noted in Table 3.2.  
Table 3.2: Liver and spleen characteristics in patients with liver lesions/masses 
Patient with liver 
lesions/masses 
Hepatomegaly Abnormal liver 
function test 
Splenomegaly Splenic lesions 
1 Yes Yes Yes Yes 
2 Yes No Yes Yes 
3 Yes Yes Yes Yes 
4 Yes Yes No Yes 
5 No No No No 
6 Yes Yes No No 
7 Yes Yes Yes No 
8 Yes Unknown Yes No 
9 No No No Yes 
 
Deranged liver function tests (LFT) such as raised ALP/GGT or ALT/AST were noted in 50 of 151 
patients (33%). In 24 patients with hepatomegaly, LFT’s were normal. Nine patients with 
abnormal liver function tests (LFT) had no hepatomegaly.                                                                                                  
Sixty of 148 patients (41%) had splenomegaly. The spleen was clinically enlarged in 47 patients 
(32%), with radiological concurrence (sonar/CT scan) in 26 of these patients (18%). In 13 
patients (9%), there was radiological splenomegaly only. Two patients had a massive 
splenomegaly. Thirty four patients (24%) had splenic lesions, defined as hypo-echoic lesions on 
sonar or hypodensities in the spleen on CT scan.  
Thirty nine patients (26%) had bone marrow infiltration by HL. Thirteen patients (11%) had 
definite granulomas in the bone marrow. One bone marrow was reported by the pathologist as 
‘suspect’ for a granuloma. Fifteen of 152 patients (10%) had extranodal disease at sites other 
than the liver, spleen or bone marrow. In eight of these patients, extranodal involvement was 
by contiguous spread, viz. five with paraspinal masses and three with pleural effusions (proven 
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on cytology or biopsy to be HL). One patient with a pleural effusion had proptosis of the right 
eye, but there was no confirmatory imaging. Three of the 15 patients (20%) were HIV positive. 
Table 3.3 highlights the sites of extranodal involvement and HIV status of patients.  
 
Table 3.3: Distribution of extranodal sites of disease and HIV status 
 
Site of disease Number of patients HIV status 
Paraspinal mass 5 One patient positive 
Pleural effusion 3 Negative 
Lytic lesions in bone 2 Negative 
Lung nodules 2 Negative 
Breast mass (bulk disease) 1 Negative 
Tonsillar mass 1 Positive 
Gastro-intestinal involvement 1 Positive 
 
One hundred and fifty six patients were evaluable for staging of disease, which was assessed 
according to the Cotswolds modification of the Ann Arbor staging system (Appendix 1). Staging 
modalities included clinical examination, CXR and abdomino-pelvic ultrasound or CT scan with 
contrast – which was the preferred modality, depending on the period of presentation and the 
modality that was available at that time. Bone marrow aspirate and trephine was done 
routinely as part of staging. Eight patients (5%) had stage I disease, 41 (26%) stage II disease, 48 
(31%) stage III disease and 59 (38%) stage IV disease (Figure 3.3). Limited/early stage disease, 
defined as stage I and II disease, was present in 31% of patients. Advanced disease, defined as 
stage III and IV disease, was present in 69% of patients. 
 
Histological subtype was noted according to the Rye classification initially and later the WHO 
classification of HL. Fifty eight patients (37%) had nodular sclerosis HL (NSHL), 71 patients (45%) 
mixed cellularity HL (MCHL), five patients (3%) NLPHL (two were actually lymphocyte 
predominant according to the Rye classification), 23 patients (15%) were ‘unclassifiable’ and 
one patient had indeterminate histology. There were no reported cases of lymphocyte-rich HL 
(LRHL) and lymphocyte-depleted HL (LDHL) in the study population. 
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                   Figure 3.3: Distribution of disease stage 
 
 
 
 
                             
               Figure 3.4: Distribution of histological subtypes in the study population     
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NSHL was the commonest subtype in younger (<40yrs), HIV negative patients (see Figure 3.5). 
MCHL was the commonest histological subtype seen in older (>40yrs), HIV negative patients, as 
well as in the HIV positive group (Figures 3.6 and 3.7).  
 
 
                         
          Figure 3.5: Distribution of histological subtypes in younger (≤40yrs), HIV negative patients 
 
 
 
                         
        Figure 3.6: Distribution of histological subtypes in older (>40yrs), HIV negative patients 
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                Figure 3.7: Distribution of histological subtypes in the HIV positive population 
 
3.2.1 Uncommon clinical manifestations 
Four patients were Coombs positive. Three of the four patients had clinical evidence of 
haemolytic anaemia. Two patients had a simultaneous diagnosis of AIHA (autoimmune 
haemolytic anaemia) and HL. One patient developed AIHA on relapse of HL. One patient 
presented with a pathological fracture of the right neck of femur. One patient had marked 
cholestasis with a sclerosing cholangitis diagnosed on liver biopsy. One patient presented with a 
simultaneous diagnosis of HL and chronic lymphocytic leukaemia (CLL).           
3.2.2 Clinical presentation of nodular lymphocyte predominant HL  
Two patients had lymphocyte predominant HL according to the Rye classification, and three 
patients were classified as NLPHL according to the current WHO classification. Patient numbers 
were too small to make any comparisons with classical HL or with NLPHL seen elsewhere. 
Patient characteristics of this sub-group are shown in Table 3.4. 
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Table 3.4: Patient characteristics of nodular lymphocyte predominant Hodgkin’s lymphoma 
histological subtype 
 
Characteristic Number of patients 
Total number of patients 5 
Male / Female 3 / 2 
HIV status All negative 
B symptoms 3 
Performance status: 0 
                                     1 
                                     2 
                                     3 
2 
1 
1 
1 
Duration of LN (range) 10-132 months 
Early stage disease 2 
Advanced disease 3 
Bone marrow involvement 0/4 patients 
Bulk disease 0 
Extranodal disease 2 (paraspinal masses) 
Complete remission 3 
Relapse 2/3 (both in year two of remission) 
Outcome: Dead 
                   Lost to follow-up 
2 (OS = 872d and 2520d) 
3 
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3.3. Blood results 
Haemoglobin (Hb), white cell count (WCC), eosinophil, lymphocyte and platelet counts, 
albumin, lactate dehydrogenase (LDH) and B₂ microglobulin levels were recorded as medians 
and ranges. Categories of blood counts, LDH and B₂ microglobulin levels were documented 
according to laboratory reference values (see table below). Categories of Hb, WCC, lymphocyte 
count and serum albumin were also documented according to the International Prognostic 
Scoring System. 
Table 3.5: Summary of blood results  
Blood parameter Median Range Categories 
Haemoglobin (g/dl) 10.05 2 - 16.1 <14 in 82/92 males (89%) 
<12 in 56/68 females (82%) 
 <10.5 in 93/160 (58%) 
White cell count (×10⁹/l) 7.5 0.3 - 34.4 <4 in 31/159 (20%) 
>11 in 45/159 (28%) 
 ≥15 in 19/159 (12%) 
Lymphocyte count (×10⁹/l) 1.42 0 – 7.5 >4 in 8/149 (5%)  
<1 in 48/149 (32%) 
<0.6 in 15/149 (10%) 
Eosinophil count (×10⁹/l) 0.00 0 – 2.04 >0.4 in 15/149 (10%) 
Platelet count (×10⁹/l) 333 16 – 889 <100 in 15/159 (9%)  
>450 in 49/159 (31%) 
Albumin (g/l) 32 18 - 52 <40 in 121/150 (81%) 
Lactate dehydrogenase (U/L) 586 256 - 4251 >500 in 86/121 (71%) 
>1000 in 16/121 (13%)  
B₂ microglobulin (mg/l) 2.6 0.1 – 22.51 >2.2 in 65/104 (63%) 
 
Most patients had anaemia. Leucocytosis and thrombocytosis were present in almost one third 
of patients. Eosinophilia was present in 10% of patients. Leucopenia was more common than 
thrombocytopenia. Lymphopenia was common, documented in almost one third of patients. 
Most patients had low albumin levels. LDH levels were raised in more than two thirds of 
patients. Raised B₂ microglobulin levels were also fairly common. 
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3.4. Treatment 
One hundred and sixty patients (98%) received combination chemotherapy as part of first line 
treatment. Two patients died of pneumonia, prior to receiving any form of anti-neoplastic 
therapy. In a third patient, it was unclear if any treatment was received prior to demise. 
Echocardiograms were not done routinely prior to commencing chemotherapy. Patients who 
had echocardiograms included those patients presenting over the age of 45 years, patients with 
a history of underlying cardiovascular disease, patients who had received cumulative doses of 
anthracyclines and were due to receive a further course of chemotherapy, and patients in 
whom cardiac examination was abnormal. 
The median number of chemotherapy cycles received at first course was eight (IQR 4-10). 
According to treatment protocols at the time, patients with early stage disease generally 
received six to eight cycles of BCVPP (BCNU, cyclophosphamide, vincristine, procarbazine, 
prednisone) and patients with advanced disease generally received eight to twelve cycles of 
combination ABVD and BCVPP (depending on individual responses). ABVD (six to eight cycles) 
for early stage disease was introduced much later in the study period. Drug dosages were 
attenuated for HIV positive patients, and individualised according to CD4 counts. Forty six 
patients (28%) received BCVPP only, 20 patients (12%) received ABVD only, and 88 patients 
(54%) were given individualised combinations of ABVD and BCVPP. Six patients (4%) received 
other forms of combination chemotherapy such as CHOP.  
Combined modality treatment was not the standard of care for early stage disease. In patients 
who received radiotherapy as part of treatment, DXT was administered post chemotherapy to 
those who had localised residual disease, and as sandwich therapy (between chemotherapy 
cycles) or post chemotherapy to sites of bulk disease. Patients who presented as medical 
emergencies due to superior vena cava syndrome and spinal cord compression received urgent 
DXT prior to chemotherapy. Twenty four patients (15%) in the study received radiotherapy as 
part of first line combined modality treatment. No patients received radiotherapy alone as 
treatment.  
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Ten patients (6%) were considered for HDCT and ASCT as part of salvage therapy. Of these 
patients, six were transplanted; two at a referral centre and four at Chris Hani-Baragwanath 
Hospital (CHBH). In the remaining four patients, it was unclear if they were transplanted, as 
these were earlier patients who were referred to another tertiary centre at the time, and were 
lost to follow up. In the transplanted patients, two died at the referral centre post transplant 
(cause unclear) and one patient died at CHBH from severe neutropenic sepsis with positive 
blood cultures for Methicillin Resistant Staphylococcus Aureus (MRSA) in the post transplant 
period. Of the remaining three patients who were transplanted at CHBH, all achieved a 
complete remission. Two are lost to follow up, but remained in remission for the four years of 
follow up. One patient still follows up at our clinic and continues to be in remission for more 
than eight years.   
Of the patients with NLPHL, both patients who presented with paraspinal masses received 
radiotherapy as part of initial combined modality treatment. One patient died from septic 
complications of paraplegia, and the other was lost to follow-up after radiotherapy. One patient 
died of influenza pneumonia (H1N1); he was in complete remission from HL. One patient who 
achieved a complete remission did not relapse in the 10 years of follow up. The fifth patient 
was lost to follow-up after relapse of disease; her remission status was unclear.  
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3.5. Treatment response  
Response to initial treatment was assessed using the modified Cheson criteria for malignant 
lymphoma (Appendix 5). Cheson’s criteria were modified according to the imaging modalities 
available at the time of assessment. Measures of response included clinical assessment, CXR, 
abdomino-pelvic ultrasound, CT scan, gallium/PET scan and repeat bone marrow trephine (if 
initially involved).  
Response was assessed on completion of first line treatment, and in the patients who died or 
defaulted on chemotherapy, the response to treatment was assessed at demise or when the 
patient was last seen, respectively. Treatment response was assessed as non-evaluable (NE) if 
patients died or were lost to follow up too early in the course of treatment for assessment, or if 
clinical examination alone was insufficient (in patients who had no further imaging, or repeat 
bone marrow trephine in cases of bone marrow involvement).  
Table 3.6 summarises treatment responses for HIV negative patients, HIV positive patients and 
one patient in whom it was unclear when HIV was contracted. More HIV positive patients died 
during chemotherapy than HIV negative patients. Default rates on chemotherapy were quite 
high, accounting for almost one third of patients. Many patients had NE response assessments; 
this was especially true for the HIV positive group. Complete response rates for the two groups 
were similar (these findings are discussed in sections 4.5 and 4.8.3). When only patients with 
evaluable disease response were assessed, the rate of a complete response (CR) was 63%, 
partial response (PR) was 18%, stable disease (SD) was 2% and progressive disease (PD) was 
17% (see Figure 3.8).  
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Table 3.6: Treatment response for HIV negative and HIV positive patients 
*CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease 
Patient groups  
(number induced) 
Subgroups Treatment response* 
HIV negative (n=123) Died on treatment = 18 (15%) 
 
Defaulted treatment = 34 (27%) 
 
 
 
Completed treatment = 71 (58%) 
 
 
 
 
Total = 123 
PD = 5 
NE = 13 
CR = 1 
PR = 7 
PD = 7 
NE = 19 
CR = 49 
PR = 9 
SD = 2 
PD = 5  
NE = 6 
CR = 50 (41%) 
PR = 16 (13%) 
SD = 2 (1%) 
PD = 17 (14%) 
NE = 38 (31%) 
HIV positive (n=36) Died on treatment = 9 (25%) 
 
 
Defaulted treatment = 12 (33%) 
 
 
 
Completed treatment = 15 (42%) 
 
 
Total = 36 
CR = 1 
PR = 1 
NE = 7 
CR = 1 
PR = 1 
PD = 1 
NE = 9 
CR = 12 
PR = 1 
NE = 2  
CR = 14 (39%)  
PR = 3 (8%) 
PD = 1 (3%) 
NE = 18 (50%) 
HIV status unclear (n=1) Completed treatment = 1 CR = 1 
Total population (n=160) Total = 160 CR = 65 (41%) 
PR = 19 (12%) 
SD = 2 (1%) 
PD = 18 (11%) 
NE = 56 (35%) 
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Response types for the 104 patients who could be clearly evaluated are depicted in Figure 3.8 
below.  
                     
                                        Figure 3.8: Initial response to treatment  
Table 3.7 highlights response assessments for disease stage and chemotherapy regimen used. 
Of the patients with progressive disease, 82% had advanced stage disease. There were no 
significant differences for treatment response between the two age categories.  
Table 3.7: Response assessments for disease stage and chemotherapy regimen 
Response type Early stage  
disease 
Advanced  
disease 
BCVPP only 
(n=28) 
ABVD only 
(n=6) 
BCVPP and 
ABVD (n=62) 
CR 69% 58% 68% 83% (5) 63% 
PR 24% 17% 25% 17% (1) 18% 
PD 7% 25% 7% - 19% 
 
Relapse of HL after first line therapy was assessable in 58 out of 65 patients who achieved a CR. 
Seven patients were lost to follow-up soon after achieving a complete remission. Thirty patients 
did not relapse within at least one year of follow up. Twenty eight patients relapsed after first 
line treatment. Of the patients who relapsed, the median time to first relapse (DFS to CR-1) in 
23 of these patients was 420 days (range 52-2739).  
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3.6. Complications 
Complications were documented in 60 patients. 83% of these patients had advanced disease, 
and 17% had limited stage disease. Most complications were acute complications related to HL. 
Specific therapy-related complications were either acute or delayed (long term). Table 3.8 
summarises these complications. 
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Table 3.8: Complications related to Hodgkin’s lymphoma and its treatment in the study 
population 
Complication Number of 
patients 
Acute complications related to HL 
Marked cytopaenias from bone marrow infiltration (requiring blood 
product/growth factor support) 
Superior vena cava syndrome 
Parasthesiae/paraplegia from paraspinal mass 
Recurrent chest infections (not related to TB) 
Persistent pleural effusion requiring pleurodesis 
Deep vein thrombosis 
Autoimmune haemolytic anaemia 
Chicken pox 
Herpes zoster (HIV negative) 
Acute hepatitis 
Pathological fracture neck of femur 
Psychosocial 
Major depression 
 
 
11 
7 
7 
5 
4 
4 
3 
2 
2 
1 
1 
5 
1 
 
Specific treatment-related complications 
Acute:  Chemotherapy-induced pneumonitis 
              Radiation-induced pneumonitis 
              Haemorrhagic cystitis post autologous stem cell transplantation  
              Dilated cardiomyopathy 
Delayed:  Hypothyroidism 
                  Glioblastoma multiforme 
                  Adenocarcinoma of the lung 
 
 
1 
1 
1 
1 
2 
1 
1 
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3.7. Outcome and factors affecting survival  
Currently, 15 patients (9%) are confirmed to be alive. Fifty one patients (31%) have died. Ninety 
seven patients (60%) could not be traced and are lost to follow up. At last visit or upon demise, 
65 patients (40%) were not in remission from their disease, 56 patients (34%) were in complete 
remission, and in 42 patients (26%) their remission status was unclear. Findings from a life table 
analysis of survival times for patients who achieved an initial complete remission, a partial 
remission, and those with progressive disease are highlighted in Table 3.9 below. Patients in CR 
did not reach 50% survival, and patients in PR did not reach 25% survival. Seventy five percent 
of the total number of patients who were assessed for treatment response were alive at 63 
months, and the population did not reach 50% survival in the analysis time. 
Table 3.9: Survival times for patients in complete remission (CR), partial remission (PR) and 
those with progressive disease (PD) 
Response category(n) 75% alive 50% alive 25% alive 
CR (65 patients) 
PR (19 patients) 
PD (18 patients) 
Total (102 patients) 
90 months 
30 months 
13 months 
63 months 
- 
77 months 
34 months 
- 
- 
- 
115 months 
- 
      
Kaplan-Meier survival plots for the entire study population, age categories, HIV categories, 
disease stage categories, histological subtypes and B symptoms are in the figures below. Older 
patients (>40yrs), HIV positive patients and patients with advanced disease (stages III and IV) 
had comparatively poorer survival rates, that reached statistical significance. Patients with B 
symptoms tended to do worse than patients without B symptoms, but this did not reach 
statistical significance. Comparison of nodular sclerosis, mixed cellularity or unclassifiable 
histological subtypes did not appear to significantly affect outcome either. 
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                              Figure 3.9: Kaplan-Meier survival plot for the study population 
 
 
  *p value = 0.0041 
        Figure 3.10: Kaplan-Meier survival plot for younger (≤40yrs) vs older patients (>40yrs) 
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  *p value = 0.0018  
                    Figure 3.11: Kaplan-Meier survival plot for early vs advanced stage disease 
 
 
                         *p value = 0.0073 
                 Figure 3.12: Kaplan-Meier survival plot for HIV negative vs HIV positive patients 
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  *p value = 0.075 
                             Figure 3.13: Kaplan-Meier survival plot for histological subtype 
 
 
  *p value = 0.108  
       Figure 3.14: Kaplan-Meier survival plot for patients with no B symptoms vs B symptoms 
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3.8. Patient subgroups 
3.8.1. Early stage disease vs advanced disease 
Patients with Ann Arbor stage I and II were grouped as limited/early stage disease (ESD). 
Patients with Ann Arbor stage III and IV were grouped as having advanced stage HL (AD). 
Disease stage was evaluable in 156 patients. More patients had advanced stage disease. 
Patients with AD had more B symptoms and a slightly poorer performance status at 
presentation than patients with ESD. MCHL was slightly more common than NSHL in patients 
with AD. Further comparisons are highlighted in the table below and will be discussed later. 
Table 3.10: Clinical and laboratory characteristics of patients with early stage disease vs 
advanced disease 
 Early Stage Disease Advanced Disease 
Number of patients (%) 49 (31%) 107 (69%) 
B symptoms 25 (53%) 92 (88%) 
Performance status : 0 
                                      1 
                                      2 
                                      3 
                                      4    
58% 
35% 
7% 
0% 
0% 
14% 
51% 
20% 
8% 
7% 
Bulk disease 13 (28%) 13 (13%) 
Subtype: NSHL 
                 MCHL 
40% 
52% 
36% 
40% 
Hb <10.5 g/dl 23% 72% 
WCC ≥15×10⁹/l 4% 15% 
Lymphocyte count <0.6×10⁹/l 4% 11% 
Albumin <40g/l 56% 89% 
LDH >500U/l 
LDH >1000U/l 
63% 
8% 
77% 
17% 
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3.8.2 Younger patients (≤40yrs) vs older patients (>40yrs) 
Patients were grouped into two age categories for purposes of analysis, with 40 years being the 
cut-off age. The most striking observation was the predominance of MCHL as the main 
histological subtype in older patients. B symptoms were equally prevalent in both age groups. 
Findings are highlighted in the table below.  
Table 3.11: Clinical characteristics of younger patients vs older patients 
 Younger patients (≤ 40yrs) Older patients (> 40yrs) 
Number of patients 125/162 (77%) 37/162 (23%) 
Advanced disease 81/121 (67%) 25/34 (74%) 
B symptoms 93/119 (78%) 28/36 (78%) 
Performance status:  0 
                                      1 
                                      2 
                                      3 
                                      4 
28% 
49% 
14% 
4% 
5% 
32% 
35% 
23% 
10% 
0% 
Bulk disease 20 (17%) 6 (17%) 
Histological subtype: NSHL 
                                      MCHL 
51 (41%) 
48 (39%) 
7 (21%) 
23 (68%) 
 
3.8.3. HIV negative vs HIV positive patients 
Forty six patients (28%) in the study were HIV positive. Six patients had a prior diagnosis of HIV 
(more than one year). In 31 patients, HIV was diagnosed simultaneously with HL. Eight patients 
contracted HIV after their HL was diagnosed. In one patient, the timing of the HIV diagnosis was 
unclear. There was no HIV result for one patient. These last ten patients were omitted for 
statistical analysis. Hence 37 patients were analysed in total.  
Similarities and differences between the HIV positive and negative groups are noted in Table 
3.12. Both groups had similar median ages at presentation of HL (see box-whisker plot and 
histogram below). HIV positive patients were concentrated in the third and fourth decades.  
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                                             Figure 3.15: Histogram for age by HIV status 
 
 
                                         Figure 3.16: Box-Whisker plot for age by HIV status 
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Table 3.12: Clinical characteristics of HIV positive vs HIV negative individuals 
 HIV positive HIV negative 
Number of patients 46 (28%) / (37 analysed) 116 (71%) 
Age (median/range) 30yrs (range 13-59) 29yrs (range 13-87) 
Male:female ratio 1.8 : 1 1.2 : 1 
CD4 count at presentation (×10⁶/l) 
 
Median = 186 
Range = 32-769 
IQR = 98-246 
N/A 
B symptoms 27 (77%) 86 (78%) 
Performance status:  0 
                                      1 
                                      2 
                                      3 
                                      4 
29% 
46% 
21% 
0% 
4% 
29% 
47% 
14% 
7% 
3% 
Advanced disease 28 (78%) 74 (67%) 
Bulk disease 4 (11%) 22 (21%) 
Bone marrow infiltration 15 (43%) 21 (20%) 
True extranodal disease 4 (13%) 13 (12%) 
Histological subtype: NSHL 
                                       MCHL 
                                       Unclassifiable 
 6/36 (17%) 
22/36 (61%) 
8/36 (22%) 
45/110 (41%) 
46/110 (42%) 
14/110 (13%) 
 TB: Total number of patients 
        Past infection 
        Active disease 
        Post treatment for HL 
11/46 (24%) 
3/11 (27%) 
7/11 (64%) 
1/11 (9%) 
30/115 (26%) 
6/30 (20%) 
21/30 (70%) 
3/30 (10%) 
Treatment response: CR 
                                       PR 
                                       PD 
                                       NE 
14/36 (39%) 
3/36 (8%) 
1/36 (3%) 
18/36 (50%) 
50/123 (41%) 
16/123 (13%) 
17/123 (14%) 
38/123 (31%) 
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The HIV positive group had a higher male: female ratio, more advanced stage disease, a much 
higher incidence of bone marrow involvement by HL and a predominance of MCHL, when 
compared to the HIV negative group. The incidence of B symptoms and extranodal involvement 
(excluding liver, spleen and bone marrow) was similar in both groups. The association with TB 
was similar for the two population groups. TB was most frequently associated with HL in both 
HIV positive and HIV negative patients (slightly more in the negative group).    
Five of the thirty seven HIV positive patients received ARV’s. One patient was on ARV’s prior to 
to the diagnosis of HL (in private), one patient started ARV’s whilst on chemotherapy for HL and 
three patients received ARV’s whilst in remission from HL. Four patients who were referred to 
the HIV clinic for ARV’s were lost to follow up. All these patients were in remission from HL. One 
patient refused referral for ARV’s due to social issues.  
Thirty six patients received induction therapy. One patient had disseminated Kaposi’s sarcoma 
and died of pneumonia prior to any chemotherapy.  
Twelve of the 37 patients (32%) have died. Of these patients, nine died early in the course of 
their disease, whilst receiving chemotherapy (see Figure 3.12, Kaplan-Meier plot). Two patients 
died from HIV-related complications (pneumocystis jerovecii pneumonia), whilst in remission 
from HL. Twenty four patients (65%) were lost to follow up. Nine of these patients were in 
complete remission from their HL at last visit. One patient with HIV-HL is currently confirmed to 
be alive and is in complete remission. 
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CHAPTER FOUR: DISCUSSION 
 
4.1. Patient characteristics in the study population 
Chris Hani-Baragwanath Hospital is a tertiary government referral hospital in Soweto. Thus, 
most of the patients in the study were from the south of Johannesburg, mainly Soweto. Other 
patients were referred from nearby areas, and a handful of patients were from neighbouring 
countries such as Zimbabwe, Swaziland and Mozambique; hence the preponderance of Black 
patients in the study population. Many patients were also of poor socio-economic standing. The 
analysis is therefore fairly representative of a developing, Black population from sub-Saharan 
Africa.  
The population group studied included adult patients as classified by hospital admission 
criteria. The youngest patient was 13 years old and the very young paediatric population was 
not really assessed here. Seventeen patients (10%) were younger than 18 years, and 28 patients 
(17%) were younger than 20 years. Fifty percent of adult patients with newly diagnosed HL at 
Chris Hani-Baragwanath Hospital from 1990-2004 were aged between 23-39 years. This concurs 
with the peak incidence of HL in young adults, found elsewhere in the world. The absence of a 
bimodal presentation, without a second peak in older patients, follows the pattern of most 
developing countries. Furthermore, the population, consisting primarily of Black South Africans, 
did not exhibit a tri-modal peak as noted in US Black males (3).  
As patients in our setting generally tend to present with malignancies about a decade earlier 
than in developed countries, and the data failed to show a peak in older patients, patients over 
the age of 40 years were grouped as older patients for purposes of comparison in the study. 
The cut-off age of 40 years was used for younger patients. Twenty three percents of patients 
were in the older age group.  
The absence of a marked gender preference, with a M:F ratio of 1.3:1, is typical of HL in adults. 
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4.2. Clinical features 
The majority of patients presented with an ECOG performance status (PS) of 1, followed by a PS 
of 0. Thus most of the patients, despite some late presentations to hospital and a significant 
number of patients with advanced disease, were quite well on presentation. B symptoms were 
prominent, reported in up to 78% of patients. This is much higher than the figure of 35% 
quoted in the paper by Connors (18), but fairly similar to a small paediatric study from Mali 
(66). Fourteen percent of patients had severe pruritis, one of whom was treated by 
dermatologists for intractable pruritis for two years before the diagnosis of HL was made. Thus, 
the diagnosis of HL must be entertained in a patient with unexplained pruritis. 
As it was difficult to accurately document the actual prevalence of TB in the study population, 
patients were divided into HIV positive and HIV negative groups, and further subdivided into 
those with a past history of TB, patients with active TB and HL, and patients who had TB post 
treatment for HL (Table 3.12). The background prevalence of TB in South Africa for 2010 was 
795/100 000 population (67). The strong association with TB for the HL study population (26% 
of patients in total) is likely to be a combination of the background prevalence of TB in the 
community, as well as an increased incidence of TB in patients with HL (as most patients in the 
study had active TB) and, more recently, the co-existence of HIV with HL. TB was extra-
pulmonary in 15 of 32 patients (disseminated in six patients), and this may suggest impaired 
immune status from HL and, in some patients, co-existing HIV infection.  
The median duration of lymphadenopathy (LN) or symptoms relating to HL (five months) was 
moderate, but the range was quite vast, with some patients still presenting fairly late to 
hospital. The majority of patients presented with supra-diaphragmatic lymphadenopathy, 
which is well described in the literature. Almost all of these patients had involvement of cervical 
lymph nodes. Thus, supra-diaphragmatic lymphadenopathy in the absence of accompanying 
cervical LN was highly unlikely to be due to HL. In more than half of the patients, 
lymphadenopathy was generalized at presentation. Thus, localized disease at presentation of 
HL was not a common finding in the study group. This was in keeping with the higher 
proportion of patients presenting with advanced stage disease. 
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Hepatomegaly and splenomegaly were equally common in the study population. The 
occurrence of splenic and liver lesions, possibly indicating involvement by disease, closely 
matched frequencies quoted in the literature, with splenic lesions being four times more 
common than liver lesions (19). The most common deranged liver function test (LFT) was a 
mildly raised ALP/GGT.  
Some enlarged livers and deranged LFT’s resolved before treatment for HL. Other reasons for 
hepatomegaly and abnormal LFT’s included liver congestion from severe anaemia in a number 
of patients, superior vena cava syndrome in patients with massive mediastinal disease, and 
occasionally fatty infiltration of the liver in HIV positive patients. This might explain why clinical 
and radiological correlation of hepatomegaly was poor, as some of these conditions may have 
been reversed prior to imaging. Though the correlation between clinical and radiological 
splenomegaly was better than for hepatomegaly, the fact that a number of clinically enlarged 
spleens were not detected radiologically cannot be explained.  
Short of a liver biopsy (which can also miss disease), actual involvement of the liver by HL is 
otherwise difficult to diagnose. HL may present in various ways in the liver, e.g. severe 
hepatitis, fulminant liver failure and marked cholestasis (68). A number of patients had mildly 
deranged ALP/GGT with no obvious cause, which resolved on treatment of HL. One of the study 
patients had a marked cholestatic picture, and was diagnosed with a sclerosing cholangitis on 
liver biopsy (see uncommon clinical manifestations below). A few patients in the study had a 
mild hepatitic picture for which no drug or viral cause was evident. One patient had a severe 
hepatitis; again no clinical cause was evident except for underlying HL.  
Table 3.2 was an attempt to exhibit a correlation between liver lesions, hepatosplenomegaly, 
deranged LFT’s and splenic lesions. Hepatomegaly was present in seven out of nine patients 
with liver lesions/masses, but there was no clear correlation between liver lesions and 
deranged LFT’s, splenomegaly or splenic lesions. Thirty nine percent of patients with 
hepatomegaly had normal LFT’s (probably for some of the reasons mentioned earlier), while 
18% of patients with abnormal LFT’s had no hepatomegaly; thus, most patients with deranged 
LFT’s on presentation were likely to have hepatomegaly. 
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The majority of patients in the study had advanced stage disease at presentation. This is in 
keeping with disease presentation in most developing countries, including parts of Africa (69, 
70). Stage IV disease was mainly due to bone marrow involvement at presentation and was less 
often due to liver and distant extranodal involvement. One third of bone marrow trephines 
contained granulomas, which were often difficult to differentiate from TB. TB was actively 
sought at other sites, and if clinically proven and CXR features were suggestive of TB, anti-TB 
therapy was instituted as well.  
Comparisons were drawn mainly between NSHL and MCHL, as these two histological subtypes 
were the most commonly seen. For the whole group, MCHL was slightly more common than 
NSHL, appearing to follow the pattern of a developing nation. However, when subgroups of 
patients were analysed, more marked differences in the frequencies of NSHL and MCHL 
became evident. When the younger, HIV negative population was assessed, NSHL was the 
commoner subtype, though still not as predominant as in first world populations. There was no 
female preference for NSHL in general. In keeping with findings elsewhere, MCHL was the 
commonest histological subtype seen in older patients and in the HIV positive population 
(Figures 3.4–3.7).  
4.2.1 Uncommon clinical manifestations 
HL and primary sclerosing cholangitis  
The association of HL and primary sclerosing cholangitis is rare, but well documented (26). An 
observation of three cases by Man et al. showed that, in all three cases, HL was diagnosed years 
after the diagnosis of sclerosing cholangitis (71). The study patient had a simultaneous 
diagnosis of both conditions, the sclerosing cholangitis being diagnosed on liver biopsy, and the 
HL diagnosed on a lymph node biopsy.   
Richter’s transformation of chronic lymphocytic leukaemia (CLL) to HL 
Richter’s transformation of chronic lymphocytic leukaemia (CLL) to HL has been well described 
in the literature, occurring with a frequency of 15% of all transformations (72). Often the 
diagnosis of HL is made months to years after the diagnosis of CLL. However, the two conditions 
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can also be diagnosed simultaneously. Sometimes, the HL clone may share features with the 
CLL clone. EBV proliferation is thought to play a role in the development of HL. Purine 
nucleoside analogues used to treat CLL have been implicated as well, but this has not been 
consistently proven (73). This type of secondary HL has a poorer prognosis than de novo HL, 
with median OS rates of 0.8 years (74). The study patient had a simultaneous diagnosis of CLL 
and HL. HL was diagnosed on LN biopsy and CLL was diagnosed on the staging bone marrow 
that was done. Unfortunately, the patient defaulted therapy after five cycles of combination 
BCVPP and ABVD (five months after diagnosis). Clinically, at last visit, neither the HL nor the CLL 
were in remission. 
Autoimmune haemolytic anaemia 
Autoimmune haemolytic anaemia (AIHA) is rare in HL (75). It can occur at any time in the course 
of HL: it may precede HL, be diagnosed simultaneously with HL, present upon relapse of HL or 
present even when HL is in remission (76). A large study of 1029 patients with HL showed an 
overall incidence of AIHA of less than one percent. Patients with AIHA on presentation of HL 
appeared to have a unique clinical profile, viz. older patients with more advanced disease and 
non-nodular sclerosing histological subtypes (75). Another smaller review, showed a male 
preponderance for AIHA in HL (76). The study patient profile, though small, may support this 
finding as two of the patients were male and one was female. However, two patients were in 
the younger age group, and one patient had early stage disease. One patient had NSHL and two 
patients had MCHL. None of the patients were HIV positive, but one patient did have a 
simultaneous diagnosis of TB, which can also be associated with an AIHA. A positive Coombs 
test does not always accompany clinically evident haemolytic anaemia, as was noted in one 
patient from the study population. 
4.2.2 Nodular lymphocyte predominant HL  
Patient numbers for this histological subtype (five in total) were too small to draw any 
adequate conclusions from the findings (see Table 3.4). However, some of the clinical features 
did differ from the classic description in the literature. No patients had localized disease, and 
the two patients with early stage disease had stage II disease. Three patients had advanced 
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disease and B symptoms. The extra-nodal presentations (viz. paraspinal masses) seen in two 
patients, were also unusual for this histological subtype. The demise of a patient many years 
later from influenza pneumonia, whilst in remission from HL, further emphasizes the prolonged 
immune suppression that patients with HL experience, as well as the need for annual influenza 
vaccination even for patients in remission. 
4.3. Blood results  
Most patients presented with anaemia (see Table 3.5). Leucocytosis was mainly on the basis of 
a neutrophilia, and was not always due to sepsis. Leucopenia and thrombocytopenia were 
mainly due to bone marrow infiltration by HL. The high B₂ microglobulin level of 22.51 was 
recorded in a patient with renal impairment.  
Variables of the IPS were documented, as more study patients had advanced stage disease. Of 
the patients with haemoglobin levels of <10.5g/l, 83% had advanced disease (p value=0.000). A 
white cell count of ≥15×10⁹/l was not common, but higher white cell counts were seen in 
patients with advanced disease without statistical significance (p value=0.058). Low lymphocyte 
counts did not appear significant. Albumin levels were <40g/l in most patients, including a large 
percentage with early stage disease. This may be a reflection of the lower albumin levels 
generally seen in our patients.  
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4.4. Treatment 
More than half of the patients in the study received individualised combinations of BCVPP and 
ABVD. This is a reflection of the number of patients with advanced disease who were treated as 
per protocol at the time. Only a few patients received ABVD alone as first line chemotherapy, 
because BCVPP was initially first line therapy in patients with early stage disease. Current 
trends are changing though. 
Patients were referred to another tertiary institution for radiotherapy. Timing of the 
radiotherapy depended on the clinical presentation of the individual patient. Involved field 
radiotherapy was not part of routine practice at the time and patients who received 
radiotherapy in the study need to be followed up closely for long term complications. 
Not many patients were transplanted at CHBH in the early days, and a number of patients were 
referred to another tertiary centre at the time. The first autologous stem cell transplant in a 
patient with HL at CHBH was in the year 2000. An increasing number of patients are currently 
receiving HDCT and ASCT at the CHBH and are the subject of a recent review, the abstract of 
which was presented at the South African Stem Cell Transplantation Society (SACeTS) 
Conference in Cape Town in February, 2012 (77). The use of ASCT as salvage therapy in HL in 
our setting will be a promising study for the future.  
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4.5. Treatment response 
Modified Cheson’s criteria were used to assess response after first line therapy. A number of 
patients could not be assessed for treatment response, either because clinical examination 
alone was insufficient for an assessment, or because patients died early, or were lost to follow-
up early in their treatment. 
Complete response (CR) rates were lower than those described in the literature (see Table 3.6 
and Figure 3.8). This is probably a reflection of the large number of patients in the population 
that had advanced stage disease at presentation. Furthermore, in a number of patients, 
compliance during treatment was erratic, and as a result treatment was often interrupted and 
not administered on time. Socio-economic circumstances often prevented patients from 
keeping to their exact follow-up dates, and also contributed to the large number of patients 
who defaulted on chemotherapy (fifty four percent of patients completed initial treatment). 
This might also partly account for the higher number of patients with progressive disease. 
The forty four percent of patients who died or defaulted on treatment accounts for the large 
percentage of non-evaluable (NE) treatment responses (much higher in the HIV positive group). 
Eighteen of 34 patients who defaulted chemotherapy, did so after cycle six of chemotherapy, 
and these patients may have actually been in remission from their disease. 
When only patients with evaluable disease response were assessed, overall response rates 
were much better – 81% (63% CR and 18% PR).  
Of note was that progressive disease (PD) was more prevalent in the advanced stage group (p 
value=0.065).  Age category did not affect treatment response. 
CR rates were quite similar for patients treated with BCVPP alone and those treated with 
combination ABVD and BCVPP (see Table 3.7). Randomised trials comparing similar regimens 
(MOPP vs ABVD alternating with MOPP) have shown superiority of the alternating regimen in 
terms of CR rates, FFP and OS (33). The findings in this study are probably because combination 
ABVD and BCVPP was used mainly in patients with advanced disease, while BCVPP alone was 
used mainly in early stage disease. Patients with ESD had slightly better CR rates than those 
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with AD (though this was not statistically significant). ABVD alone was used in too few patients 
to really compare with other regimens.  
Fifty eight of 65 patients who achieved a CR could be assessed for relapse of disease. Twenty 
eight of these patients relapsed. Of the patients who relapsed, the median time to first relapse 
(DFS to CR-1) in 23 of these patients was 420 days (range 52-2739).  
4.6. Complications 
The high rate of acute complications related to HL, such as severe cytopaenias and superior 
vena cava syndrome (see Table 3.8), may be an indication of the aggressive/advanced nature of 
the disease at presentation in the study population.  
Though the acute therapy-related complications were less common, some important points can 
be noted from these. The development of a subclinical cardiomyopathy has been well described 
in patients who receive moderate doses of anthracyclines not exceeding the limit of toxicity, 
usually at a median of eight years follow-up (49). The study patient developed an overt 
cardiomyopathy (with recurrent episodes of congestive heart failure) early in the course of her 
treatment, not having reached toxic doses of anthracycline therapy, and prior to receiving 
mantle field radiotherapy. She was a young female in her early twenties with no overt risk 
factors for cardiac disease. The development of subclinical hypothyroidism after radiotherapy in 
this patient may have potentially worsened the cardiac manifestations later on.  
The patient who developed a chemotherapy-induced pneumonitis was a seventy year old 
elderly female. The most likely cause in this patient was an idiosyncratic reaction to bleomycin. 
This complication has been well described in elderly patients and needs to be considered when 
deciding on chemotherapy in the older patient with HL. The same patient developed an 
adenocarcinoma of the lung 14 months after treatment for HL was completed. This 
complication was more likely related to the strong smoking history of the patient, as it 
presented fairly soon after chemotherapy. There was no history of thoracic radiation for HL, but 
alkylating agents were part of chemotherapy. Whether the presentation of the lung malignancy 
was accelerated by HL or its therapy provides some food for thought.  
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The presentation of a glioblastoma multiforme occurred  in a patient who was initially treated 
with combination chemotherapy for HL at the age of 13, and then again upon relapse 7.5 years 
later. He had no history of cranial irradiation. Glioblastoma multiforme is a well documented 
second malignancy in patients surviving cancer. Usually, but not always, it is associated with 
radiation, either to the cranium or rarely to sites adjacent to the spine, including mediastinal 
radiotherapy (78, 79). The patient was followed up for his intra-cranial malignancy by the 
neurosurgeons, and was unfortunately lost to follow-up at the clinical haematology 
department. 
The study population is now at the time for surveillance for long term complications of therapy. 
Unfortunately, most patients have been lost to follow-up, and our personal experience 
regarding long term toxicity of treatment modalities used in our patients has been very limited. 
4.7. Outcome and factors affecting survival 
The five year overall survival for the population assessable for treatment response was 75%. 
Initial response to treatment had some impact on patient survival, with patients who achieved 
a CR not reaching 50% survival, and those who achieved a PR not reaching 25% survival in the 
life table analysis (see Table 3.9). Older patients, patients with advanced disease and HIV 
positive patients had significantly poorer survival rates (see Figures 3.9-3.14). 
Almost a third of patients have died. Contributing factors are probably the high number of 
patients with advanced disease and the erratic follow-up for treatment in a number of patients.  
All the patients who are alive are currently in remission from their disease. The high rate of 
patients who are lost to follow up is cause for concern, especially since these patients cannot 
be monitored for therapy-related complications. Furthermore, it does make accurate 
assessment of disease free progression and overall survival problematic, which will impact on 
the optimal management of our patient population in the future.  
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4.8. Patient sub-groups 
4.8.1. Early stage disease vs advanced disease 
Table 3.10 summarises the characteristics of the two groups. A large number of patients (69%) 
had advanced stage disease on presentation. This did not include stage IIB patients with extra-
nodal and bulk disease who, according to the GHSG, would also be classified as having 
advanced disease. This presentation is consistent with studies in other parts of Africa (69, 70). B 
symptoms were present in almost all patients with AD. All the study patients with a 
performance status of 3 and 4 had AD, suggesting that some of these patients were 
(expectedly) more ill at presentation. Conversely, patients with early stage disease were 
relatively well at presentation to hospital. Haemoglobin levels of <10.5g/dl were seen in a 
significant number of patients with AD compared to early stage disease (p value = 0.000). While 
most patients with AD had albumin levels less than 40g/l, a number of patients with ESD had 
low albumin levels too, and the difference was not statistically significant. As expected, higher 
LDH levels (>1000U/l) were recorded in the group with advanced disease, indicating higher 
disease burden. Interestingly, no histological subtype preference was seen, indicating that 
advanced stage was a feature of the study population in general. Patients with AD had 
significantly poorer survival than patients with ESD (Figure 3.11). 
4.8.2. Younger patients (≤40yrs) vs older patients (>40yrs) 
While the classification of older patients was not the same as in the literature (where patients 
over the age of 55-60 years are classified as older), significant comparisons could be made, 
indicating that perhaps the cut-off age of 40 years is acceptable for analysis in our population 
(see Table 3.11). Older patients had more advanced stage disease, which is well described. 
Mixed cellularity HL was by far the commonest histological subtype, which is also well 
documented in older patients elsewhere. B symptoms and bulk disease were equally prevalent 
in older and younger patients. Also, there were no marked differences in performance status at 
presentation. Older patients had a significantly poorer survival outcome than younger patients 
(Figure 3.10). 
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4.8.3. HIV positive patients vs HIV negative patients 
The first study patient diagnosed with HIV and HL was in 1994. Over the 15 year study period, 
23% of newly diagnosed patients with HL were HIV positive (37 patients in total). This is similar 
to the prevalence rate of HIV-HL of 19.5% found by Stein et al. in a South African cohort, which 
included patients from our centre, for the period 1995-2004 (80). In a recent two year review at 
CHBH from July 2008 to June 2010, the HIV sero-prevalence of newly diagnosed patients with 
HL was 67% (9). This is a reflection of the marked increase in prevalence of HIV infection in 
South Africa during these two different study periods. The prevalence of HIV in South Africa in 
1995 was 4.5%, and in 2011 it was 10.6% (81). 
The median age at presentation for HIV-HL was 30 years (IQR 25-36yrs). Most patients were 
young, highlighting the peak incidences for both HL and HIV in younger patients. However, even 
fewer HIV positive patients were older than 40 years, probably because most patients at the 
time of the study were ARV naïve and did not live long. The box-whisker plot and histogram for 
age by HIV status demonstrates these similarities and differences quite clearly (Figures 3.15 and 
3.16). 
The slight male predominance for HIV-HL in the study population is unexplained. The 2008-
2010 review at CHBH showed a slight male predominance (M:F ratio of 1.1:1). The marked male 
predominance of more than 80% found in other series probably reflects the high prevalence of 
HIV in intravenous drug users and homosexual males, while the main mode of transmission in 
South Africa is by heterosexual contact (9). Also, the HIV prevalence in South Africa is higher in 
females than males: 10.9% vs 9.1% in 2005 and 12.6% vs 9.2% in 2011 (81).  
Most patients with HIV-HL had B symptoms and advanced stage disease. However, the 
prevalence of B symptoms was the same as in the HIV negative population, while the 
percentage of HIV positive patients with advanced disease was higher than in the HIV negative 
patients (see Table 3.12).  
The median CD4 count at presentation was lower than that quoted in most studies, but 
consistent with the findings at CHBH in 2008-2010 (9). All the patients, except for one, were 
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ARV naïve at the time of diagnosis of HL. This is probably because 31 of the 37 patients had a 
simultaneous diagnosis of HIV and HL. Furthermore, anti-retroviral (ARV) therapy was only 
made available to patients at CHBH towards the end of 2004. Though 45% of the patients in the 
later review were on ARV’s, those patients still had lower CD4 counts at diagnosis of HL. 
MCHL was the commonest histological subtype seen in HIV-HL, with an even higher incidence 
than in the recent series at CHBH (9). NSHL was the second commonest histological subtype. 
Surprisingly, there were no patients with lymphocyte depleted HL (LDHL), and this could not be 
explained, as this subtype is supposed to be seen with an increased incidence in HIV-HL. A 
number of patients had disease that could not be classified, and whether some of these were 
actually of the lymphocyte depleted subtype needs to be considered. The recent 2008-2010 
series of HIV-HL from CHBH showed a prevalence of LDHL of eight percent (2/24 patients), and 
more recently, unpublished data has revealed another patient with HL of the lymphocyte 
depleted subtype who has been diagnosed at CHBH.    
The high incidence of bone marrow involvement is typical of HIV-HL. Of the patients with other 
extra-nodal sites of disease, one had gastro-intestinal involvement and one patient a tonsillar 
mass. These are unusual sites of extra-nodal presentation for HL, which is also well described in 
HIV-HL. 
The percentage of patients with TB was similar for the HIV positive and HIV negative groups, 
and this is probably a reflection of the high background prevalence of TB in the community in 
general (see Table 3.12). Slightly more HIV negative patients had active TB than HIV positive 
patients. The reason for this is probably that there were many more HIV negative than HIV 
positive patients in the study. In the 2008-2010 review of HIV-HL at CHBH, the proportion of 
patients with TB, and active TB, in HIV-HL was more than double than in the HIV-HL study 
population here (59% vs 24% and 38% vs 15%). This is most likely a reflection of the increased 
background prevalence of TB from 377/100 000 population in 1995 to 795/100 000 population 
in 2010 (67). 
Overall response rates (CR and PR) were only slightly better for the HIV negative group 
compared to the HIV positive group – 54% vs 47% (see Table 3.12). The reason for this is 
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probably that the HIV positive group was much smaller than the HIV negative group, and fifty 
percent of the HIV positive group also had a NE treatment response. The large number of HIV 
positive patients with a NE treatment response can be attributed to the patients who died and 
defaulted early on during treatment.  
More HIV positive patients died on treatment than HIV negative patients. Nine out of twelve 
HIV positive patients who died in the study, died on chemotherapy, and seven of these patients 
died early on within four cycles of chemotherapy. The fact that the majority of these patients 
had bone marrow involvement by HL and were not on HAART must have contributed to these 
deaths, as six of these patients died from worsening cytopenias on chemotherapy, and sepsis 
consequent on the neutropenia.  
Almost a third of HIV-HL patients have died. The majority of these patients died early on during 
the first course of chemotherapy (despite attenuated doses of chemotherapy). This is clearly 
demonstrated in the Kaplan-Meier survival plot (Figure 3.12). Clearly demonstrated in the plot 
also, is the significantly superior survival of HIV negative patients over HIV positive patients in 
the study (p value = 0.0073). 
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4.9. Study limitations 
Being a retrospective study, there were some limitations.  
As data was collected from patient records, there was always an element of some missing data 
for each variable. Fortunately, patient numbers were large enough to still make reasonable 
inferences from the data.  
Erythrocyte sedimentation rate (ESR) results were not available for a number of patients, and it 
would have been useful to assess their utility as part of the IPS in patients with advanced 
disease, especially in patients with concomitant HIV or TB, as both these conditions can raise 
the ESR. Similarly, EBV studies were not done routinely at the time, and these would have been 
useful to assess positivity in the study population, especially the HIV positive group. 
PET scans have become available at the CHBH in the last few years only, and therefore criteria 
for treatment response assessments had to be modified according to imaging modalities 
available at the time for each patient. An attempt was made to be as uniform as possible when 
assessing the treatment responses. Therefore, a number of patients could not be included for 
assessment of treatment response, as clear assessments could not always be made on available 
data/imaging. 
The large number of patients who are lost to follow-up has impacted on the accurate 
assessment of treatment response, disease-free survival and overall survival. It has also 
resulted in limited experience regarding the long term toxicities of treatment modalities used in 
the study population.        
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CHAPTER FIVE: CONCLUSION 
 
The main aim of this study was to document the demographics and clinical features of adult 
patients with Hodgkin’s lymphoma at CHBH, and to compare these findings with findings 
elsewhere in the world. This study has shown that the presentation of HL in adults at CHBH 
exhibits shared characteristics of developed and developing nations, though mainly those of a 
developing nation. Another important finding was the higher prevalence of TB in the study 
population (HIV positive and negative patients) compared to the background prevalence in the 
community, supporting the positive association of HL and TB. The initial response to treatment 
impacted on survival, with patients achieving a complete response to treatment displaying 
longer survival times than those with a partial response, who had better survival times than 
patients with progressive disease. Other prognostic factors affecting survival in the study 
population included age of patient, stage of disease and HIV status.  
New trends in the management of HL at CHBH are emerging. With the increasing use of HDCT 
and ASCT in patients with relapsed/refractory disease at CHBH, it will be interesting to assess 
the impact on patient outcome in the future. The increasing availability of PET/CT scans for 
response assessment will aid in the optimal management of our patient population, whilst at 
the same time limiting treatment-related toxicity. Furthermore, the increasing numbers of 
patients with HIV-HL, as well as the accessibility to combined anti-retroviral therapy (cART) for 
all these patients, is now revolutionising the management of this subgroup of patients at CHBH, 
and it will be interesting to reassess disease characteristics and outcome for these patients in 
the future. 
The large number of patients lost to follow-up continues to be cause for concern, especially 
since many of these patients are probably well and disease outcome and therapy-related 
complications cannot be adequately assessed. The importance of completing treatment and 
continuing long term follow-up needs to be stressed to patients at all times, and contact details 
for patients need to be carefully documented and updated at each visit. 
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APPENDICES 
 
APPENDIX 1  
Ann Arbor staging classification (Cotswolds modification) (28) 
  
Stage 1 Invovement of a single lymph node (LN) region/structure (eg. spleen, thymus, 
waldeyer’s ring) or single extralymphatic site (1E) 
Stage II Involvement of 2 or more LN regions on the same side of the diaphragm; 
localised involvement of 1 extranodal organ/site and LN regions on the same 
side of the diaphragm (IIE); number of anatomical sites indicated by a subscript, 
eg. II₃ 
Stage III Involvement of LN regions/structures on both sides of the diaphragm, which may 
also be accompanied by localised involvement of an extranodal organ/site (IIIE), 
involvement of spleen (IIIS) or both (IIISE) 
III₁ ± involvement of spleen, splenic hilar, celiac or portal nodes 
III₂ With involvement of para-aortic, iliac or mesenteric nodes 
Stage IV Diffuse involvement of 1 or more extranodal sites (eg. bone marrow, liver or 
other extranodal sites not contiguous with LN – cf. ‘E’ below). 
A Absence of constitutional symptoms 
B Fevers >38:C, weight loss >10% in 6 months or drenching night sweats 
Additional subscripts applicable to any disease stage:  
X Bulky disease (widening of mediastinum by >33% or mass ≥10cm) 
E Involvement of a single extranodal site contiguous or proximal to known nodal 
site    
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APPENDIX 2  
Unfavourable criteria  for limited stage Hodgkin’s lymphoma (33) 
 
 
 
 
 
 
 
 
 
 
GHSG = German Hodgkin Study Group 
EORTC = European Organisation for Research and Treatment of Cancer 
ESR = erythrocyte sedimentation rate 
 
 
 
 
 
 
 
 
 
 
 
                                        GHSG                         EORTC                            
 
               Large mediastinal mass              Large mediastinal mass  
              High ESR              High ESR  
              ≥4 sites              ≥3 site 
                            Age ≥50                Extranodal disease 
                  Massive splenic disease 
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APPENDIX 3 
International prognostic scoring system (IPS) / Hasenclever index for advanced Hodgkin’s 
lymphoma (33) 
 
Adverse Prognostic factors 
1) Age ≥45 years 
2) Stage IV 
3) Male sex 
4) White blood count ≥15 000 cells/µl 
5) Lymphocyte count <600 cells/µl or <8% 
6) Albumin <4.0 g/dl 
7) Haemoglobin <10.5 g/dl 
   
 
Number of factors  5 year FFP (%)          5 year OS (%) 
(Outcome according to prognostic score) 
      
 0 
 1 
 2 
 3 
 4 
 ≥5 
 
 
84 
77 
67 
60 
51 
42 
 
 
89 
90           
81 
78 
61 
56 
FFP = freedom from progression 
OS = overall survival 
 
 85 
 
 
APPENDIX 4 
WHO / ECOG performance status (19) 
 
0 
1 
 
2 
 
3 
 
4 
Fully active; able to carry on all pre-disease performance without restriction. 
Restricted in physically strenuous activity, but ambulatory and able to carry out 
work of a light or sedentary nature, eg. light housework, office work. 
Ambulatory and capable of all self-care but unable to carry out any work activities; 
up and about more than 50% of waking hours. 
Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours. 
Completely disabled; cannot carry on any self-care; totally confined to bed or chair. 
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APPENDIX 5 
Revised response criteria for malignant lymphoma, 2007 
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